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1. Introduction 
 
The liver is the largest organ of the body and fulfills complex functions. Its strategic 
location in relation to the blood drained from the intestinal tract and the unique functions 
of hepatocytes allow it to serve as a filter that prevents passage of absorbed toxins into 
the systemic circulation (McCuskey 2006; Michalopoulos 2007). 
  
1.1 Structure of the liver 
 
1.1.1 Liver anatomy 
 
The mouse liver is located in the cranial part of the abdominal cavity with a convex surface 
facing the diaphragm and a concave surface facing the abdominal viscera (Thoolen et al. 
2010). It accounts for 5-6% of the total mouse weight. The liver has a dual blood supply: 
venous blood delivered by the portal vein and arterial blood delivered by the hepatic 
artery. The portal vein carries non-oxygenated blood collected from the gastrointestinal 
tract, spleen as well as pancreas and contributes with 75% of the total blood supply of the 
liver. The hepatic artery delivers oxygenated blood and contributes with 25% of the total 
blood supply of the liver (Hollander et al. 1987; Vollmar and Menger 2009). The liver is 
connected to the intestine via the common bile duct which carries bile from the gall 
bladder to the duodenum (McCuskey 2006). The mouse liver consists of four lobes: left, 
median, right and caudate (figure 1.1). The left lobe is the largest of the mouse liver. The 
median lobe is connected to the diaphragm via the coronary ligament (Fiebig et al. 2012) 
and is divided by incomplete fissure into two segments where the gall bladder is located 
in between. The right lobe is subdivided horizontally into anterior and posterior portions. 
The caudate lobe is located at the visceral surface and subdivided into two-small 
segments (Hollander et al. 1987). 
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Figure 1. 1: Anatomy of the mouse liver. The liver occupies the cranial third of the abdominal cavity just 
caudal to the diaphragm (A). It consists of four lobes: left, right, median and caudate (B and C) (Source: 
Elsevier Inc., WWW.Netterimages.com). 
  
 
1.1.2 Liver histology 
 
The liver consists of repetitive functional units called lobules (figures 1.2 and 1.3). 
Branches of the portal vein and the hepatic artery carry the blood to the periportal region 
of the liver lobule. The blood then flows through the liver sinusoids toward the central vein 
into the center of the liver lobule. In contrast, bile flux occurs in the opposite direction and 
leaves  the liver lobule in the periportal region via the bile duct (Ishibashi et al. 2009). The 
liver lobule consists of both parenchymal and non-parenchymal cells. The orchestrated 
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cooperation between these cells allows the liver to fulfill its functions as well as to 
efficiently regenerate the lost liver mass following injury. 
Figure 1. 2: Blood supply and structure of the liver lobule. The liver lobule receives its blood supply at 
the periportal region via branches of the portal vein and hepatic artery. The blood then flows into the 
sinusoids (arrows) and drains into the central veins which collect into the liver vein. In contrast, the bile duct 
which receive bile from the bile canaliculi leaves the liver lobule at the periportal area (Source: 
https://herbsforhealthandwellbeing.files.wordpress.com/2014/01/bile-caniculi.jpg). 
 
1.1.2.1 Hepatocytes 
 
Hepatocytes (parenchymal cells) are polygonal epithelial cells arranged in 1-2 cell thick 
plates separated by the blood sinusoids. Hepatocytes make up 80% of the liver mass and 
approximately 60-65% of the total liver cells number (Gebhardt 1992). The average 
diameter of hepatocytes is 25-30 µm (McCuskey 2006). Although hepatocytes are 
homogeneous from the histological point of view, they display heterogeneous functions 
according to their location along the porto-central axis of the liver lobule (Jungermann 
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and Kietzmann 1996). There are two well-known metabolic zones in the liver lobule: the 
periportal zone (zone 1) which involves hepatocytes surrounding the portal vein, and the 
pericentral zone (zone 3) involving hepatocytes surrounding the central vein (figure 1.3). 
Hepatocytes in these compartments display different functions. For example, urea 
synthesis is restricted to the periportal hepatocytes, in contrast glutamine synthesis is 
restricted to the pericentral hepatocytes (Gebhardt 1992). Moreover, gluconeogenesis 
occurs predominantly in the periportal area, while glycolysis is most predominant in the 
pericentral zone (Katz et al. 1977). 
Hepatocytes are polarized epithelial cells with basolateral and apical domains (Wang and 
Boyer 2004). The basal membrane which faces the sinusoids has microvilli to increase 
the surface area and facilitate the exchange of materials between hepatocytes and blood 
(figure 1.3). The apical membrane forms the bile canaliculi with the adjacent hepatocytes 
and also possess microvilli to increase the surface area for bile secretion. Polarity is a 
critical feature for hepatocytes functions. 
 
 
Figure 1. 3: Cellular composition and zonation of the liver lobule. The liver lobule (A) is formed of four 
major cell types (B): (1) hepatocytes which are arranged in cords and separated from the blood by 
sinusoidal endothelial cells (2). The basal (facing the endothelial cells) and apical (facing the neighboring 
hepatocyte) membranes of hepatocyte form microvilli to increase the surface area. The space between 
hepatocytes and endothelial cells is called Disse space in which another cell type is located called hepatic 
stellate cells (3). In addition, Kupffer cells (4) are resident within the sinusoidal lumen. The liver lobule 
contains two distinct metabolic zones: zone 1, involving the periportal hepatocytes, and zone 3, involving 
the pericentral hepatocytes. In addition, there is a less distinct midzonal area in between (zone 2). (Source: 
modified from Reif et al. 2017). 
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1.1.2.2 Liver sinusoidal endothelial cells 
 
Liver sinusoidal endothelial cells (LSECs) represent a unique type of endothelial cells 
lacking the basement membrane that are fenestrated (Malarkey et al. 2005). They form 
a barrier between blood and hepatocytes and are separated from hepatocytes by the 
space of Disse (figure 1.3). LSECs represent approximately 20% of the total liver cells 
number and 2.8% of the liver volume (Gebhardt 1992). Fenestration of LSECs allows it 
to control the exchange of fluids and molecules between blood and hepatocytes. 
Moreover, LSECs play a critical role in liver injury by secretion mitogenic factors (e.g. 
HGF), which are important for liver regeneration (Ding et al. 2014). 
 
1.1.2.3 Kupffer cell 
 
Kupffer cells (KC), the liver specific macrophages, are located within the sinusoidal lumen 
(figure 1.3).  It account for 8-12% of the total liver cells number and 2.1% of the liver mass 
(Gebhardt 1992; te Koppele and Thurman 1990). Beside their phagocytic functions, KC 
play a critical role in liver diseases as they secrete pro-inflammatory cytokines like TNF-
α and IL-6 which amplify liver inflammation and affect other liver cells (Ishibashi et al. 
2009; Ramadori et al. 2008). 
 
1.1.2.4 Hepatic stellate cells 
 
Hepatic stellate cells (HSCs), also called Ito cells or fat storing cells, are located in the 
Disse space between hepatocytes and LSECs in healthy liver (figure 1.3). They form 
about 5% of the total liver cells number and approximately 1.4% of the liver volume 
(Stockert and Wolkoff 2001). The primary function of HSCs is to store vitamin A and lipids 
(Malarkey et al. 2005; Senoo 2004). Upon liver injury HSCs get activated, 
transdifferentiate into myofibroblast like cells, proliferate and migrate to the site of injury 
where they play a critical role in liver regeneration and fibrosis including production of 
cytokines, growth factors as well as extracellular matrix (ECM) (Bataller and Brenner 
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2005; Pellicoro et al. 2014; Senoo 2004). 
 
1.1.2.5 Biliary epithelial cells 
 
Biliary epithelial cells (BECs) form the lining of the bile ducts which carry bile from bile 
canaliculi to the gall bladder and then to the intestine. It account for approximately 3-5% 
of the total liver cells number (Ishibashi et al. 2009). It contribute to the final composition 
and volume of bile (Maroni et al. 2015). 
 
1.1.2.6 Liver associated lymphocytes  
 
In addition to the aforementioned cells, the liver is also enriched in lymphocytes especially 
natural killer (NK) cells (initially known as pit cells) and natural killer T (NKT) cells. They 
are resident in the sinusoidal lumen. NK cells provide a line of defense against viral 
infection and tumors as well as anti-fibrotic action (Nakatani et al. 2004; Seki and 
Schwabe 2015). 
 
1.2  Acetaminophen induced liver injury: state of the art 
 
Acetaminophen (paracetamol, APAP) is a safe antipyretic and pain relieving drug when 
used at therapeutic doses (Bessems and Vermeulen 2001; Jaeschke et al. 2011; McGill 
et al. 2012; Saito et al. 2010). It can be metabolized by sulfation catalyzed by 
sulfotransferase (SULT) or glucuronidation catalyzed by UDP-glucuronosyltransferase 
(UGT) leading to products which can easily be excreted (Hinson et al. 2010; Jaeschke 
2005). In contrast, overdoses of APAP are commonly associated with acute liver injury 
both in humans and animals (Bessems and Vermeulen 2001; Jaeschke et al. 2011; McGill 
et al. 2012). High doses of APAP are metabolized in hepatocytes by cytochrome P-450 
enzymes especially the CYP2E1 isoform into a toxic reactive metabolite named N-acetyl-
p-benzoquinone imine (NAPQI) (figure 1.4) (Bessems and Vermeulen 2001; Hinson et al. 
2010). NAPQI can be trapped by conjugation to glutathione via glutathione-S-transferase 
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forming glutathione adduct which is safely excreted. Therefore, N-acetyl cysteine is a 
standard treatment for APAP overdose as it enhance glutathione synthesis (Mitchell et al. 
1973). However, high doses of APAP can deplete hepatic glutathione allowing NAPQI to 
form covalent bonds with cellular and mitochondrial proteins and non-protein thiols which 
compromise mitochondrial respiration and triggers the release of reactive oxygen species 
(ROS) (Bessems and Vermeulen 2001; Jollow et al. 1973; McGill et al. 2012; Saito et al. 
2010). This leads to formation of peroxynitrite in mitochondria (Jaeschke et al. 2003; 
Jaeschke et al. 2011) as well as activation of C-Jun NH2-terminal kinase (JNK), a critical 
factor in death signaling. Once activated, JNK translocates to the mitochondria where it 
binds to a scaffold protein in the outer mitochondrial membrane called SAB (Han et al. 
2013). This results in further amplification of mitochondrial oxidative stress and 
peroxynitrite formation which triggers the mitochondrial membrane permeability transition 
(MPT) leading to loss of mitochondrial function. Furthermore, apoptosis inducing factor 
(AIF), endonuclease G and cytochrome C are released from the compromised 
mitochondria and translocate to the nucleus where they induce DNA fragmentation 
leading to cell death (Bajt et al. 2011; Jaeschke et al. 2003; Jaeschke et al. 2011). 
It was reported recently (Guicciardi et al. 2015) that receptor interacting protein kinase 1 
(RIPK1) contributes to APAP induced liver injury by activation of JNK. However, the 
mechanisms of RIPK-1 induced JNK activation are currently unknown (Guicciardi et al. 
2015). 
It should also be considered that the release of fragmented DNA as well as cellular 
proteins, for example high mobility group box 1 (HMGB1), from damaged hepatocytes 
can stimulate Kupffer cells to produce pro-inflammatory cytokines leading to infiltration of 
immune cells especially neutrophils which can further amplify APAP induced liver injury 
(Jaeschke 2005; Marques et al. 2015; Williams et al. 2010). Due to the restricted zonation 
of CYP2E1 to the pericentral region of the liver lobule, this compartment is considered to 
be the primary target of APAP toxicity. 
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Figure 1. 4: Mechanisms of acetaminophen (APAP) induced liver injury. High doses of APAP are 
metabolized mainly by CYP2E1 into a reactive metabolite called N-acetyl-p-benzoquinone imine (NAPQI) 
which bind to mitochondrial proteins and initiate oxidative stress. This results in peroxynitrite formation in 
the mitochondria, activation and translocation of the death signaling JNK to the mitochondria. Activation of 
JNK further amplify oxidative stress and peroxynitrite formation leading to induction of mitochondrial 
permeability transition. As a consequence, apoptosis inducing factor (AIF), endonuclease G and 
cytochrome C are released from the mitochondria and translocate to the nucleus where they induce DNA 
damage leading to cell death. The release of damaged DNA to the blood can attract immune cells 
particularly neutrophils which may further amplify liver inflammation and hepatocytes death. 
 
1.3  Response of the liver to injury: the switch from regeneration to fibrosis 
 
The liver fulfills vital functions of the body particularly metabolic homeostasis and 
xenobiotics detoxification. Therefore, it is capable to perform a rapid well-orchestrated 
response upon exposure to injury (Friedman 2012; Michalopoulos and DeFrances 2005; 
Taub 2004). However, the response of the liver is highly dependent on the duration of 
injury. For example single exposure to carbon tetrachloride (CCl4), a hepatotoxic agent 
that targets the pericentral hepatocytes, is followed by an efficient regenerative response 
and full recovery of the dead cell area within a week (Ghallab et al. 2016; Hoehme et al. 
2010). In contrast, repeated exposure to CCl4 leads to liver fibrosis (Iredale 2007). 
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In response to liver injury HSCs get activated and migrate to the site of injury (Iredale et 
al. 1998). Activated HSCs are the major source of extracellular matrix (ECM) and 
represent the bottle neck between perfect regeneration and fibrosis (figure 1.5). Acute 
liver damage leads to a transient activation of HSCs which disappear after regeneration 
of the dead cell area. In contrast, chronic liver damage leads to compromised 
regeneration and prolonged activation of HSCs resulting in excessive deposition of ECM 
and liver fibrosis (Xu et al. 2014). 
 
 
 
 
 
 
 
 
 
Figure 1. 5: Hepatic stellate cells (HSCs) dynamics after liver injury. Following liver injury HSCs 
transdifferentiate into myofibroblast-like cells and migrate to the site of injury where they produce 
extracellular matrix leading to liver fibrosis. However, depending on the duration of injury, this process can 
be reversible. After cessation of liver injury activated HSCs disappear by apoptosis or by reversion to a 
quiescent phenotype. 
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1.3.1 Liver regeneration 
 
Hepatocytes in adult healthy liver are mostly quiescent; the proliferation rate is less than 
1% (Taub 2004). In contrast, upon liver injury hepatocytes undergo proliferation leading 
to full recovery of the dead cell area within a week (Hoehme et al. 2010). Such a rapid 
regenerative response takes place at the cellular, the lobule as well as the organ level. At 
the cellular scale, both the parenchymal as well as the non-parenchymal cells cooperate 
in order to guarantee efficient regeneration of the lost liver mass (figure 1.6). Upon liver 
injury, some gut-derived factors like lipopolysaccharide (LPS) reach the liver via the portal 
vein. (Michalopoulos and DeFrances 2005; Taub 2004). This leads to stimulation of 
Kupffer cells to produce pro-inflammatory cytokines like IL-6 and TNF-α which provide 
the ideal environment for immune cell infiltration, which prepare the ground for efficient 
regeneration process (Bohm et al. 2010; Taub 2004). The LSECs play a critical role in 
liver regeneration. (Ding et al. 2014), reported that the stromal derived factor-1 receptors 
CXCR7 are upregulated in LSECs upon acute liver injury. This leads to induction of the 
transcription factor Id1 and production of mitogenic factors such as Wnt2 and hepatocyte 
growth factor (HGF) which trigger hepatocyte proliferation. Moreover, Hoehme et al, 2010 
showed that the newly formed hepatocytes align in the direction of the closest sinusoid; 
a mechanism which is essential for perfect regeneration. Although HSCs are dangerous 
in case of chronic liver injury, a transient activation is important for efficient liver 
regeneration (Shen et al. 2011). The production of ECM help to form a temporary scar at 
the site of injury which prevents the wound collapse. Moreover, activated HSCs produce 
HGF which stimulates hepatocytes proliferation (Forbes and Rosenthal 2014). It should 
also be considered that the hepatic cells also receive extra- hepatic support such as 
insulin from the pancreas and epidermal growth factor (EGF) from the duodenum and the 
salivary glands (Taub 2004).  
Regeneration at the lobule level is influenced by the type of injury. After loss of pericentral 
hepatocytes (e.g. after APAP or CCl4 intoxication) the remaining periportal hepatocytes 
proliferate and the dead cell area is restored within 6 days (Hoehme et al. 2010). In 
contrast, surgical removal of some liver lobules leads to a different scenario. The mass 
of the lost liver lobules is restored by increasing the size of the remaining ones 
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(Michalopoulos 2007; Taub 2004). At the organ scale, the liver body weight ratio serves 
as a control system that triggers the turn-off signals once the original mass of the liver is 
restored (Michalopoulos 2007). 
 
Figure 1. 6: Liver regeneration at the cellular level. Upon liver injury endothelial cells and Kupffer cells 
are activated to secrete pro-inflammatory cytokines like IL-6 and TNF-α which prime hepatocytes for 
proliferation. Subsequently, endothelial cells and stellate cells secrete HGF which is a potent hepatocyte 
mitogen. Once the dead cell area is restored stellate cells release TGF-β which terminate liver regeneration 
via suppression of the cell cycle (Source: https://www.dkfz.de/en/systembiologie/projekte.html). 
 
1.3.2 Liver fibrosis 
 
Liver fibrosis is a wound healing response in case of chronic liver injury (Pellicoro et al. 
2014). It characterized by excessive accumulation of ECM particularly collagen type I and 
III. Activated HSCs are the major source of ECM (Mallat and Lotersztajn 2013; 
Ramachandran and Iredale 2012a). Following liver injury, cellular and molecular changes 
occur leading to trans-differentiation of the quiescent HSCs into myofibroblasts-like cells. 
Activated HSCs are highly proliferative and acquire the ability to migrate to the site of 
injury and to produce collagen (Bataller and Brenner 2005; Iredale 2007; Iredale et al. 
1998; Kong et al. 2013). Activation of HSCs is orchestrated mainly by interaction with 
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immune cells (discussed in details below). The spatial expression of ECM in the liver 
lobule depends on the etiology of liver injury. In cholestatic liver disease [e.g. primary 
biliary cirrhosis (PBC) and primary sclerosing cirrhosis (PSC)] ECM deposition occurs 
originally in the periportal compartment of the liver lobule (Pollheimer et al. 2014). In 
contrast, repeated exposure to hepatotoxins, which target the pericentral hepatocytes 
(e.g. CCl4) leads to collagen deposition originally in the pericentral area (Bataller and 
Brenner 2005; Henderson and Iredale 2007; Ramachandran and Iredale 2012a). 
Depending on the duration of injury fibrosis can be reversible (figure 1.7). The reversibility 
of liver fibrosis is regulated by the balance between matrix metalloproteinases (MMPs) 
and their tissue inhibitors TIMPs (Liedtke et al. 2013). If the injury is sustained, this leads 
to permanent upregulation of TIMPs and excessive accumulation of ECM and further 
progression into cirrhosis and finally liver failure (Bataller and Brenner 2005; Forbes and 
Rosenthal 2014; Pellicoro et al. 2014). In contrast, when the causative agent is removed, 
this leads to activation of MMPs and fibrosis regression (Mallat and Lotersztajn 2013; 
Ramachandran and Iredale 2012a; Tacke and Trautwein 2015). Fibrosis regression 
occurs in two steps (figure 1.5): (1) elimination of activated HSCs, and (2) degradation of 
ECM. Elimination of activated HSCs occurs via three mechanisms: first, senescence of 
activated HSCs which leads to a phenotype with reduced fibrogenic properties and 
increased susceptibility to killing by immune cells (Kim et al. 2013; Krizhanovsky et al. 
2008). Second, apoptosis which is mediated mainly by NK cells (Gur et al. 2012; Radaeva 
et al. 2006); third, reversion to the quiescent state, however, these cells remain in “a stand 
by position” and have the potential for rapid fibrogenesis if the injury is repeated 
(Friedman 2012; Kisseleva et al. 2012; Troeger et al. 2012). Degradation of ECM is 
mediated by MMPs which are mainly produced by the restorative macrophages 
(Fallowfield et al. 2007; Ramachandran and Iredale 2012b; Ramachandran et al. 2012). 
Dendritic cells and endothelial cells contribute also to MMPs production (Tacke and 
Trautwein 2015).  
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Figure 1. 7: Reversibility of the liver fibrosis. Liver fibrosis develops following chronic liver injury. 
Depending on the duration of injury it can progress into cirrhosis and finally liver failure. However, cessation 
of liver injury may allow fibrosis regression in early stages (Source: Pellicoro et al. 2014). 
 
1.3.3 Interaction of immune cells with hepatic stellate cells  
 
Immune cell infiltration is a typical feature to all kinds of liver injury. In addition to their role 
in liver injury and regeneration they can closely interact with HSCs. Several types of 
immune cells (figure 1.8) are critical for promoting activation or inactivation/ killing of 
HSCs, thereby controlling fibrogenesis and fibrosis regression processes. 
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Figure 1. 8: Major cell types which interact with HSCs during fibrogenesis and fibrosis regression. 
Activation of HSCs is triggered mainly by pro-inflammatory macrophages, whereas, elimination of activated 
HSCs is induced mainly by restorative macrophages, natural-killer cells, gamma delta T-cells and dendritic 
cells. 
  
1.3.3.1 Role of macrophages 
 
Macrophages play a key role both during fibrogenesis and fibrosis resolution 
(Ramachandran and Iredale 2012b; Tacke and Zimmermann 2014) (figure 1.9). The 
infiltrating macrophages can be differentiated from the liver resident Kupffer cells by the 
high expression of CD11b (CD11bhi)  (Ramachandran  et  al.  2012).  Kupffer  cells  are  
predominant in healthy liver and decrease upon injury. Based on expression of LY6C, the 
infiltrating macrophages can be further classified into two-distinct populations: (1) 
CD11bhi Ly6Chi (pro-inflammatory macrophages) which are predominant during fibrosis 
progression, and (2) CD11bhi Ly6Clo (restorative macrophages) which infiltrate during 
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fibrosis resolution (Ramachandran and Iredale 2012b; Ramachandran et al. 2012; Tacke 
and Zimmermann 2014). Similar macrophage phenotypes have been described during 
liver damage and regeneration after an acute challenge (Zigmond et al. 2014). Depletion 
of these macrophage populations in animal models of liver fibrosis reveals distinct 
opposing roles during fibrosis progression and resolution. 
 
Role of pro-inflammatory macrophages 
 
Depletion of CD11bhi Ly6Chi macrophages during fibrogenesis lead to reduced stellate 
cells activation (Baeck et al. 2014; Duffield et al. 2005). This is because pro-inflammatory 
macrophages produce the pro-inflammatory cytokine TGF-β which activate the quiescent 
HSCs into myofibroblasts-like cells (Duffield et al. 2005; Ramachandran and Iredale 
2012b; Seki et al. 2007). In addition, the Ly6Chi macrophages produce platelet-derived 
growth factor (PDGF) which promotes proliferation and migration of HSCs to the site of 
injury (Ramachandran and Iredale 2012b; Wang et al. 2016). Furthermore, the pro-
inflammatory macrophages maintain the survival of activated stellate cells via production 
of the pro-inflammatory cytokines IL-1β and TNF-α which are  potent stimulators for NFk-
B pathway (Pradere et al. 2013) (figure 1.9). 
 
Role of restorative macrophages 
 
In contrast to Ly6Chi macrophages, depletion of Ly6Clo macrophages during fibrosis 
recovery leads to failure of ECM degradation (Duffield et al. 2005; Ramachandran et al. 
2012). The restorative macrophages can induce killing of activated HSCs in a TRAIL 
dependent manner (Fischer et al. 2002). In addition, they are also a rich source of MMPs 
especially MMP9, MMP12 and MMP13 which induce ECM degradation (Ramachandran 
et al. 2012; Tacke and Zimmermann 2014) (figure 1.9). 
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Figure 1. 9: Role of macrophages during fibrogenesis and fibrosis resolution. There are two-different 
macrophages phenotypes during fibrosis progression and resolution: (1) the pro-inflammatory 
macrophages, which are recruited during fibrosis progression and are critical for activation (by TGF-β 
secretion), proliferation (by PDGF secretion) and survival (by TNF-α and IL-β secretion) of hepatic stellate 
cells (HSCs). (2) The restorative macrophages, which are recruited during fibrosis recovery and are 
important for killing of activated HSCs (in a TRAIL dependent manner) and degradation of ECM (by 
production of MMPs) (Source: Pellicoro et al. 2014). 
 
1.3.3.2 Role of dendritic cells 
 
Depletion of dendritic cells (DCs) during fibrosis progression by injection of diphtheria 
toxins into transgenic mice carrying diphtheria toxins receptors under the direction of 
CD11C promoter revealed that DCs do not contribute to fibrosis development (Pradere 
et al. 2013). In contrast, removal of DCs during the fibrosis recovery phase lead to delayed 
fibrosis resolution (Jiao et al. 2012). This was supported by accelerated fibrosis resolution 
when the number of DCs was increased either by adoptive transfer or by injection of Fms-
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related tyrosine kinase 3 ligand (FLT3LG) which is known to induce the expression of 
DCs (Masten et al. 2004). DCs enhance fibrosis regression either directly by production 
of MMP9 (figure 1.9) or indirectly via stimulation of NK cells by production of IFN-γ (Jiao 
et al. 2012; Lukacs-Kornek and Schuppan 2013). 
 
1.3.3.3 Role of Natural killer cells 
 
Natural killer (NK) cells belong to innate lymphoid cells group 1 and play a critical role in 
controlling viral hepatitis, tumorigenesis as well as liver fibrosis (Gao et al. 2009; Tian et 
al. 2013). The cytotoxic action of NK cells is controlled by the balance between inhibitory 
and stimulatory receptors expressed on its surface and the corresponding ligands 
expressed on the target cells (Fasbender et al. 2016; Tian et al. 2013) (figure 1.10). The 
stimulatory receptors are NKG2D, NKP46, NKP44 and NKP30. They interact with the 
activating ligands expressed on the target cells including MICA and retinoic acid early 
inducible 1 (RAE1) leading to NK cell activation. Inhibition of NK cells is mediated by the 
inhibitory receptors LY49A and NKG2 in mice which interact with the major 
histocompatibility complex class 1 (MHC-1) molecule expressed on the target cells 
leading to NK cells suppression. Additionally, NK cell cytotoxicity is also regulated by 
several cytokines. Examples for cytokines which induce NK cells activation are type-1 
IFNs, IFN-γ, IL-2, IL-15, IL-12 and IL-18. In contrast, TGF-β and IL-10 are potent inhibitors 
for NK cell (Gao and Radaeva 2013; Tian et al. 2013). 
Several studies showed that activation of NK cells ameliorate liver fibrosis (Gao et al. 
2009; Radaeva et al. 2006). This was confirmed by enhanced liver fibrosis when NK cell 
is blocked by administration of specific antibodies. NK cells can kill HSCs either directly 
by expression of the death receptors ligands TRAIL or by production of cytokines 
particularly IFN-γ (Radaeva et al. 2006). It was reported that NK cells kill only the early 
activated and senescent stellate cells but not the quiescent and the fully activated HSCs 
(Gao et al. 2009). However, it should be considered that this was based on in vitro 
experiments. 
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Figure 1. 10: Regulation of natural killer (NK) cells. NK cells are controlled by the balance between 
inhibitory (LY49A and NKG2) and stimulatory (NKp46, NKp30, NKp44 and NKG2D) receptors and the 
interaction with the corresponding ligands (RAE1, MICA or MHC1) expressed on the target cells. In addition, 
NK cells can be activated or suppressed by cytokines. The NK cells stimulatory cytokines are Type I IFNs, 
IFN-γ, IL-2, IL-15, IL-12, IL-18, TLR ligands. In contrast, TGF-β, IL-10 are potent NK cells inhibitors. 
 
1.3.3.4 Role of Innate lymphoid cells 
 
Innate lymphoid cells (ILCs) are a group of innate immune cells belongs to lymphocytes 
but lacks a B or T cell receptors (Zook and Kee 2016). Little is known about their role in 
liver fibrosis. Based on their products ILCs can be subdivided into three groups: group 1, 
which include NK cell, produce mainly IFN-γ and TNF-α. Group 2, produce mainly IL-4, 
IL-5, IL-9 and IL-13 (Artis and Spits 2015; Zook and Kee 2016). (McHedlidze et al. 2013), 
reported that this group is involved in fibrosis progression by activation of HSCs in IL-13 
dependent manner. Group 3 ILCs are mainly present in the intestinal tract and produce 
TNF, IL-17A and IL-22 (Artis and Spits 2015). 
 
 
1. Introduction 
19 
 
1.3.3.5 Role of Neutrophils 
 
It is well known that neutrophils play a critical role in amplification of liver damage 
(Marques et al. 2015). However, it has no role neither in the activation nor in the killing of 
HSCs (Moles et al. 2014). Induction of fibrosis in transgenic mice lacking the myeloid 
related proteins, which are important for recruitment of neutrophils to the site of injury, 
respond in a similar way as the wild type mice. 
 
1.3.3.6 Role of the adaptive immune cells 
 
The role of T cells in liver fibrosis was discussed controversially. Mice lacking T cells 
(CD4+, CD8+ and γδ-T cell) have unaltered fibrosis induced by repeated administration of 
hepatotoxins (Henderson and Iredale 2007; Novobrantseva et al. 2005; Seki and 
Schwabe 2015). However, a recent study (Hammerich et al. 2014) utilizing mice lacking 
γδ-T cell showed that they are important for fibrosis resolution. The anti-fibrotic action of 
γδ-T cell is mediated by killing of activated HSCs in a Fas-Ligand dependent. 
B-cell represents 50% of intrahepatic lymphocytes (Seki and Schwabe 2015). Utilizing 
mice deficient in B cells, it was reported that they are important for fibrosis progression 
(Novobrantseva et al. 2005). B cells enhance fibrogenesis in an immunoglobulin and T 
cells independent manner. This is because using mice which have normal number of B 
cells but are deficient in immunoglobulins or T cells developed similar fibrosis as in the 
wild type mice. 
 
 
 
 
 
 
 
 
1. Introduction 
20 
 
1.4 Aim of the work 
 
Fibrotic regeneration is a wound healing response in case of chronic liver injury. In 
contrast, perfect liver regeneration occurs following acute damage without deposition of 
any detectable extracellular matrix. Although the mechanisms of hepatic stellate cell 
(HSC) activation and elimination are extensively studied during liver fibrosis and fibrosis 
recovery, little is known about the role of HSC following acute liver injury. The overarching 
goal of this thesis is to investigate HSC dynamics during liver injury and regeneration 
following an acute challenge and to identify the mechanisms that protect against liver 
fibrosis. The work program on path to this goal is structured into the following tasks: 
· Study liver injury and regeneration following intoxication with a single high dose of 
acetaminophen (APAP) as a model of acute liver injury. 
· Identify the liver resident as well as infiltrating immune cells during liver injury and 
regeneration which might interact with HSC. 
· Investigate HSC activation following liver injury and their fate during recovery. 
· Study the impact of macrophage depletion during liver regeneration on HSC 
clearance. 
· Identify the possible backup mechanisms that protect against liver fibrosis after 
macrophage removal. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Chemical Company 
123 count eBeads ebioscience, San Diego, California  
United States 
 
2-Methylbutane Sigma-Aldrich Corp., St. Louis, MO, USA 
 
2-propanol Carl Roth, Karlsruhe, Germany 
5-Bromo-2-deoxyuridine (BrdU) Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Acepromazine Fatro, Ozzano Emilia (BO), Italy 
Acetaminophen Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Acetic acid Carl Roth, Karlsruhe, Germany 
Albumin bovine fraction V Carl Roth, Karlsruhe, Germany 
Aquatex mountig agent Merk, Darmstadt, Germany 
Carbon tetrachloride Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 
DAPI, 4,6 diamidino 2 phenylindole Invitrogen GmbH, Karlsruhe, Germany 
Disodium hydrogen phosphate  Applichem GmbH, Darmstadt, Germany 
 
DPBS (Ca/Mg-free)  Life Technologies (Thermo Scientific), 
Braunschweig, Germany 
 
Entellan Merk, Darmstadt, Germany 
Eosin Y disodium salt Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Ethanol, absolute Carl Roth, Karlsruhe, Germany 
Ethyline diamine tetra acetic acid 
disodium salt (EDTA) 
Sigma-Aldrich Corp., St. Louis, MO, USA 
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FluorPreserve Reagent EMD Millipore, Billerica, USA 
Glucose Sigma-Aldrich Corp., St. Louis, MO, USA 
HI-FCS PAN-Biotech, Aidenbach, Germany 
Histo acryl B\Braun, Tuttingen, Germany 
Hydrochloric acid 4 mol/L Carl Roth, Karlsruhe, Germany 
Hydrogen peroxide 30% Carl Roth, Karlsruhe, Germany 
Ketamin-ratiopharm 50 mg  Ratio pharm, Ulm, Germany 
Leica tissue freezing medium Leica Microsystems, Wetzlar, Germany 
Mayer´s Hemalum solution Merk, Darmstadt, Germany 
Methanol Carl Roth, Karlsruhe, Germany 
Methanol free formaldahyde Carl Roth, Karlsruhe, Germany 
NEG-50 tissue freezing medium Thermo Scientific, Braunschweig, 
Germany 
 
OneComp eBeads ebioscience, San Diego, California  
United States 
 
Paraffin histowax Leica Microsystems, Wetzlar, Germany 
Percoll Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Potassium chloride  Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Potassium dihydrogen phosphate Sigma-Aldrich Corp., St. Louis, MO, SA 
Roti-histo-fix 4 % Carl Roth, Karlsruhe, Germany 
Roti-histol Carl Roth, Karlsruhe, Germany 
RPMI-1640 medium (RPMI) PAN-Biotech, Aidenbach, Germany 
Sodium acetate anhydrous Carl Roth, Karlsruhe, Germany 
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Sodium chloride  Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Sodium hydroxide  Merk, Darmstadt, Germany 
Tris Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
Trizma Hydrochloride  Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Trypan blue working solution Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Tween 20 Sigma-Aldrich Corp., St. Louis, MO, USA 
 
Tween 80 Sigma-Aldrich Corp., St. Louis, MO, USA 
 
UltraComp eBeads ebioscience, San Diego, California  
United States 
 
UltraPure 0.5M EDTA, pH 8.0 Thermo Scientific, Braunschweig, 
Germany 
 
Xylazine 2% Bayer health care, Leverkusen, Germany 
 
Zombie Red 
 
Biolegend, Koblenz, Germany 
 
2.1.2 Consumables 
  Material      Company 
Cover glass Thermo Scientific, Braunschweig, 
Germany 
Cell strainer 70um (50Stk) VWR, Darmstadt, Germany 
Cryomold tissue-Tek  Science services GmbH, Munchen, 
Germany 
Dako pen DakoCytomation, Glostrop, Denmark 
Embedding cassettes   Carl Roth, Karlsruhe, Germany 
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Falcon tube  Sarstedt, Numbrecht, Germany 
Filter paper Carl Roth, Karlsruhe, Germany   
Gentle MACS C Tubes  Miltenyi, Bergisch Gladbach, Germany 
Inject – f B\Braun, Wertheim, Germany 
Microscopic slides Thermo Scientific, Braunschweig, 
Germany 
Pipette tip Sarstedt, Numbrecht, Germany 
Safe seal tubes Sarstedt, Numbrecht, Germany 
Serological pipettes Sarstedt, Numbrecht, Germany 
Sterican - 0,3   x 12 – 30 g x ½ B\Braun, Wertheim, Germany 
24-well plate  Sarstedt, Numberecht, Germany 
96-Well assay plate Corning Incorporated, USA  
 
2.1.3 Instruments 
  Instrument      Company 
Balance BL150S  Sartorius AG, Göttingen, Germany 
Confocal laser scanning microscope Olympus BX61 microscope, Hamburg, 
Germany 
Cool centrifuge   Thermo Scientific, Braunschweig, 
Germany 
EC 350 – modular tissue embedding 
center 
Microm, Walldorf, Germany 
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Fluorescence microscope BX41 Olympus, Hamburg, Germany 
Gentle MACS Octo Dissociator Miltenyi, Bergisch Gladbach, Germany 
 
HM 450 sliding microtome  Microm, Walldorf, Germany 
Incubator Binder GmbH, Tuttlingen, Germany 
Leica CM 3050s-cryostate  Leica Microsystems, Wetzlar, Germany 
Micro plate reader, infinite M200 PRO Tecan, Switzerland 
Microwave  Sharp Electronics (Europe) GmbH, 
Hamburg, German 
pH meter lab 850 S1 analytics GmbH, Mainz, Germany 
Shaker  Rocking Platform, VWR 
Spin tissue processor STP 120 Microm, Walldorf, Germany 
Steam cooker Braun, Germany 
Stirrer IKA RCT classic, Germany 
Vibratome Leica VT 1000S Leica Microsystems, Wetzlar, Germany 
Vortex Beyer GmbH, Dusseldorf, Germany 
Water bath  GFL, Burgwedel, Germany 
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2.1.4 Buffers and solutions 
1X Acetate buffer, pH 5.2 · 6.48 g of sodium acetate anhydrous 
· 1 L of distilled H2O 
· 1.21 ml of 100% glacial acetic acid  
 
0.01 M Citrate buffer, pH 6.0  
 
· 2.1 g citric acid monohydrate 
· Filled up to 1 L with distilled H2O  
· set to pH 6 with NaOH  
 
0.1M Tris/ HCl, pH 7.6 · 15.76 g trizma hydrochloride 
· Filled up to 1 L with distilled H2O 
· Set pH  to 7.6 with NaOH 
 
0.3% BSA in 3% tween 80 in 
PBS 
· 300 mg BSA  
· 3 ml Tween 80  
· Filled up to100 ml 1X PBS 
 
10 mmol/L Tris buffer, 1 
mmol/L EDTA (pH 9.0) 
· 12.114 g Tris  
· 372.2 mg Na2EDTA  
· Filled up to 1 L with distilled H2O 
 
10x TBS, pH 7.4 · 80 g NaCl 
· 2 g  KCl 
· 30 g Tris 
· Filled up to 5 L with distilled H2O 
 
1X PBS/BSA  · 1 g BSA   
· 2.03 g NaCl 
· 100 ml of 1X PBS  
 
1x TBS-T · 1L 1X TBS, 
· 5 ml Tween 20 
 
3% BSA in 3% tween 80 in 
PBS 
· 3 g BSA  
· 3 ml Tween 80  
· Filled up to 100 ml with 1X PBS 
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3%PFA: PBS · 150 ml of roti-histo-fix 4 % 
· 50 ml 1X PBS 
 
4% Paraformaldehyde 
methylene free 
· 26.66 ml of 30% methylene free 
formaldehyde  
· 173.34 ml 1X PBS 
 
4% PFA: 30% glucose (1:1) · 30 g of glucose 
·  filled up to 100 ml with 1X PBS  
· Add 100 ml roti-histo-fix 4% 
 
Blocking buffer  
 
· Fc block (CD16/32 antibody) 1:100 in 
FACS buffer 
 
Blocking solution for 
endogenous peroxidases 
· 667 µL of hydrogen peroxide (H2O2 30%)   
· 200 ml of methanol 
 
EDTA (anti-coagulant) · 32 mg Na2EDTA    
· 1 ml distilled H2O 
 
Eosine 1% · 1 g Eosin Y disodium salt  
· 100 ml distilled H2O 
· 1 drop glacial acetic acid 
 
FACS buffer 
 
· 500 ml PBS  
· 10 ml FCS-HI  
· 2 ml 0,5 M EDTA 
· Set pH to 8   
  
FC wash medium   
 
· RPMI-1640 medium 
· 1% Pen/Strep 
 
Full RPMI-1640 medium 
 
· RPMI-1640 wash medium  
· 10% FCS (heat inactivated) 
 
Lympholyte-M 
 
· 72 mL  original Percoll solution  
· 8 mL 10X sterile PBS  
· 120 mL wash medium 
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2.1.5 Commercial kits 
 
Kit Company 
AEC+ high sensitivity substrate 
chromogen 
 
DakoCytomation, Glostrop, Denmark 
Alanine aminotransferase assay kit Sigma-Aldrich Corp., St. Louis, MO, 
USA 
 
Aspartate aminotransferase assay kit Sigma-Aldrich Corp., St. Louis, MO, 
USA 
 
Avidin and biotin blocking kit Vector laboratories, Burlingame, USA 
 
Clodronate Liposomes and PBS 
Liposomes per 10ml 
Clodronate Liposomes, Netherlands, 
Amsterdam 
Mouse anesthesia · 64 mg/kg ketamine 5% 
· 7.2 mg/kg xylazine 2% 
· 1.7 mg/kg acepromazine 
· Filled up to 1 ml with 1X PBS  
 
NaCl 0.85% · 8.5 g NaCl  
· Filled up to 1L with distilled H2O 
 
NaOH 10 M · 40 g NaOH  
· 100 ml distilled H2O  
 
Normal donkey serum Jackson Immuno-Research Laboratories, 
USA 
 
Normal goat serum Vecctor laboratories, Burlingame,USA 
 
Normal swine serum 
 
Vecctor laboratories, Burlingame,USA 
PBS (10x) 
 
· 10 g KCl  
· 10 g KH2PO4  
· 400 g NaCl  
· 46 g Na2HPO4  
· Filled up to 5 L with  distilled H2O  
· Set pH to 7.4 
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DAB substrate kit  Vector laboratories, Burlingame, USA 
 
Dako envesion+system-HRP (AEC) 
mouse kit 
 
DakoCytomation, Glostrop, Denmark 
 
Dako envesion+system-HRP (AEC) 
rabbit kit 
 
DakoCytomation, Glostrop, Denmark 
 
DeadEnd colorimetric TUNEL kit  Promega, Mannheim, Germany 
 
DeadEnd fluorometric TUNEL kit  Promega, Mannheim, Germany 
 
Liver Dissociation Kit mouse 
 
Miltenyi, Bergisch Gladbach, 
Germany 
 
MaxFluor mouse on mouse 
immunofluorescence detection kit 
MaxVision Biosciences, Dianova, 
Hamburg, Germany 
 
Peroxidase-conjugated streptavidin Jackson Immuno-Research 
Laboratories, Dianova, Hamburg, 
Germany 
 
Picrosirius red stain kit Polyscience Europe GmbH, 
Eppelheim, Germany 
 
Red blood cell lysis ACK Thermo Scientific, Braunschweig, 
Germany 
 
RQ1 RNase-free DNase Promega, Mannheim, Germany 
 
 
2.1.6 Antibodies 
2.1.6.1 Primary antibodies 
2.1.6.1.1 Primary antibodies used in Immunohistochemistry staining 
 
Antibody Company Catalog number 
Polyclonal rabbit anti-
human CD3  
DakoCytomation, Glostrop, 
Denmark 
 
A0452 
DPPIV/CD26 ectodomain  R&D system, Minneapolis, 
MN, USA 
AF954 
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Monoclonal mouse anti 
human smooth muscle 
action (clone 1A4) 
DakoCytomation, Glostrop, 
Denmark 
 
 
M0851 
Mouse monoclonal anti-
alpha smooth muscle actin 
(clone 1A4) 
 
Abcam, Cambridge, UK Ab7817 
Rabbit polyclonal antibody 
anti-cytochrome P450 2E1 
Enzo Life Sciences GmbH, 
Stressgen, Victoria, BC, 
Canada 
ADI-MFO-100 
Rabbit polyclonal anti-
alpha smooth muscle actin 
Abcam, Cambridge, UK Ab5694 
Rabbit polyclonal anti-
desmin 
 
Thermo Scientific, 
Braunschweig, Germany 
RB-9014-P0 
Rat anti-BrdU (clone 
BU1/75) 
 
AbD Serotec, Bio-Rad, 
Puchheim, Germany 
MCA2060 
Rat anti-human/mouse 
CD45R (B220) purified 
(clone RA3-6B2) 
 
eBioscince, Frankfurt am 
Main  
Germany 
14-0452 
Rat anti-mouse CD45 
(clone 30-F11) 
 
BD Bioscience, Heidelberg, 
Germany 
550539 
Rat anti-mouse F4/80 
(clone Cl:A3-1) 
 
AbD Serotec, Bio-Rad, 
Puchheim, Germany 
MCA497 
Rat anti-mouse LY6G 
(clone 1A8) 
BD Bioscience, Heidelberg, 
Germany 
 
551459 
 
2.1.6.1.2 Primary antibodies used in flow cytometric staining 
 
Antibody + Fluorophore 
 
Company Catalog number 
CD11c - BV421 Biolegend, Koblenz, 
Germany 
117329 
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CD11b - BV510 Biolegend, Koblenz, 
Germany 
101245 
CD45 - PerCP 
 
Biolegend, Koblenz, 
Germany 
103130 
 
NK1.1 - BV421 
 
Biolegend, Koblenz, 
Germany 
108732 
 
CD19 - BV510 
 
Biolegend, Koblenz, 
Germany 
115545 
 
CD4 -FITC 
 
Biolegend, Koblenz, 
Germany 
100510 
 
CD8 - PE 
 
Biolegend, Koblenz, 
Germany 
100708 
 
CD3 - AF700 
 
Biolegend, Koblenz, 
Germany 
100216 
 
Fc blocker (CD16/32 
Antibody) 
 
Biolegend, Koblenz, 
Germany 
101302 
 
 
2.1.6.2 Secondary antibodies 
 
Antibody Company Catalog number 
Alexa Fluor 647 affinipure 
F(ab)2 fragment donkey 
anti-rat IgG (H+L) 
Jackson Immuno-Research 
Laboratories, Dianova, 
Hamburg, Germany 
 
712-606-153 
Biotinylated rabbit anti-rat 
IgG (H+L) 
Vector laboratories, 
Burlingame, USA 
 
BA-4001 
Cy3 affiniPure F(ab)2 
fragment donkey anti-rabbit 
IgG (H+L) 
 
Jackson Immuno-Research 
Laboratories, Dianova, 
Hamburg, Germany 
711-166-152 
Donkey F(ab)2 anti-goat 
IgG (H+L)-alexa fluor 488 
Jackson Immuno-Research 
Laboratories, Dianova, 
Hamburg, Germany 
 
705-546-147 
Polyclonal swine anti-rabbit 
immunoglobulin/HRP 
DakoCytomation, Glostrop, 
Denmark. 
 
P0217 
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2.2  Methods 
2.2.1 Animal models of liver damage 
2.2.1.1 Experimental animals 
 
8-10 weeks old male C57Bl/6N mice, 20-25 g weight, were used (Janvier labs, 
France). The mice were fed ad libitum with Ssniff R/M-H, 10 mm standard diet 
(Ssniff, Soest, Germany) and housed at controlled ambient temperature of 25◦ C 
with 12 h day, 12 h night cycles. All experiments were approved by the local animal 
ethics committee. 
 
2.2.1.2 Induction of acute liver damage by acetaminophen 
 
In order to induce acute pericentral liver damage in mice, various doses of 
acetaminophen (50 up to 500 mg/kg as indicated in the results section) were 
dissolved in warm PBS and injected intraperitoneally (i.p.). The application volume 
was 20 ml/kg. The mice were either fed ad libitum or overnight fasted before APAP 
administration as indicated in the results section. Three to five mice were used for 
each dose and time point. 
 
2.2.1.3 Induction of acute liver damage by CCl4 
 
For induction of liver damage in mice by CCl4, a dose of 1.6 g/kg was injected i.p. 
in olive oil (1:4). The application volume was 4 ml/kg. The mice were fed ad libitum 
before and after CCl4 administration. Three mice were used for each time point. 
 
2.2.1.4 Induction of chronic liver damage by CCl4 
 
In order to induce liver fibrosis in mice, a dose of 1 g/kg CCl4 dissolved in olive oil 
(1:4) was administered i.p. twice a week for two months. The mice were fed ad 
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libitum along the entire experimental period. Following the last CCl4 dose, three 
mice were scarified time dependently up to day ten. 
   
2.2.2 Macrophages depletion 
 
Depletion of macrophages was done by intravenous tail vein injection of clodronate 
containing liposomes (50 mg/kg) (Clodronate liposomes.org) either before or after 
APAP injection as indicated in the results section. For long-term depletion of 
macrophages the injection was repeated every three days. The protocol is based 
on that liposomes can be easily phagocytosed by macrophages. Clodronate can 
then be released and accumulated within macrophages after disruption of the 
liposomal membranes by the influence of lysosomal phospholipases. After 
exceeding a threshold concentration, it induces macrophages killing by apoptosis 
(figure 2.1) (Wang et al. 2009).  
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Figure 2. 1: Mechanism of clodronate-induced macrophages killing. After phagocytosis of 
liposomes by macrophages, their membrane is disrupted by the action of liposomal phospholipase. 
This lead to release and accumulation of clodronate within macrophages. When a certain 
concentration was reached, clodronate can induce macrophages apoptosis. (Source: Wang et al. 
2009). 
 
2.2.3. Mouse surgery and samples collection 
At the indicated time points mice were anaesthetized by an i.p. injection of 
ketamine (64 mg/kg), xzylazine (7.2 mg/kg) and acepromazine (1.7 mg/kg). After 
loss of all mouse reflexes, the skin was dissected and a midline incision was made 
in the abdominal wall below the sternum. 
Blood samples were collected from three positions in mice according to Ghallab et 
al. (2016): (1) the portal vein (representing 75% of the liver inflow), (2) the liver 
vein (representing the liver outflow), and (3) the right heart chamber (representing 
the mixed venous blood). For exposure of the liver vein the median liver lobe was 
reflected cranially, whereas the left liver lobe was pushed caudally. The tip of a 30 
gauge needle was inserted in the vein and approximately 200 µl of blood were 
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collected. In order to expose the portal vein the abdominal viscera was genteelly 
pulled outside the abdominal cavity while the left as well as the median liver lobes 
were reflected cranially. The tip of a 30 gauge needle was directed against the 
direction of the blood flow and approximately 200 µl of blood were slowly collected. 
In order to collect heart blood a 26 gauge needle was passed through the 
diaphragm and the tip was inserted in the right heart chamber. All blood samples 
were collected in a syringe pre-coated with EDTA (50 µl/ml blood) to prevent blood 
coagulation. Subsequently, the blood was centrifuged in a cool centrifuge for 10 
min at 13.000 rpm and plasma was separated and stored at -80◦ C until analysis. 
Following blood collection the whole liver was excised. Samples were collected 
from defined anatomical positions (figure 2.2) as follow: (1) pieces of approximately 
20 mg were collected from the median liver lobe and were snap-frozen in liquid 
nitrogen and stored at -80◦ C for later analysis. (2) A piece of 1-2 cm size was 
collected from the median liver lobe and fixed in 4% paraformaldehyde (PFA) for 
48 h at 4◦ C. Subsequently, the samples were transferred to a solution of 30% 
glucose and 4% PFA (1:1) and stored at 4◦ C for later preparation of vibratome 
slices. (3) A piece from the left liver lobe was mounted with cryomold tissue-tek 
and rapidly frozen in isopentane. The samples were subsequently stored at -80◦ C 
until preparation of cryo sections. (4) A piece of 1-2 cm was collected from the left 
liver lobe and fixed in 4% PFA for 48 h at 4◦ C. Subsequently, the samples were 
washed with PBS and embedded in paraffin using a spin tissue processor STP 
120 embedding automate (Microm, walldorf, Germany). The used embedding 
program is shown in table 2.1. In order to further prepare the samples for cutting, 
solid paraffin blocks were made using EC 350-modular tissue embedding center 
(Microm, walldorf, Germany). 
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Figure 2. 2: Sites of samples collection from the liver lobes. A piece from the median liver lobe 
was used for preparation of vibratome slices. Another piece from the median lobe was snap frozen 
and stored at -80◦ C until used for glutathione analysis. The left liver lobe was divided into two 
pieces; one was used for preparation of cryo section and the other was used for preparation of 
paraffin sections. 
 
Table 2. 1: Embedding program of the mouse liver tissue 
Step Treatment Time (min) 
1 70%  Ethanol 30 
2 70%  Ethanol 60 
3 90%  Ethanol 30 
4 90%  Ethanol 30 
5 99%  Ethanol 30 
6 99%  Ethanol 35 
7 99%  Ethanol 60 
8 Xylol 30 
9 Xylol 35 
10 Xylol 60 
11 Paraffin histowax 80 
12 Paraffin histowax 105 
 
 
2.  Materials and methods 
 
37 
 
 
2.2.4 Transaminases assay 
 
2.2.4.1 Alanine transaminase assay 
 
Alanine transaminase (ALT) was measured colorimetrically in plasma separated 
from heart blood using a commercially available kit according to the manufacturer’s 
instructions (Sigma-Aldrich Corp., St. Louis, MO, USA). ALT catalyzes the 
reversible transfer of an amino group from alanine to alpha-ketoglutarate 
producing pyruvate and glutamate. Pyruvate was detected in an enzymatic 
reaction that converts a colorless probe into a color that can be detected at 570 
nm wavelength with the aid of a microplate reader. The intensity of color 
development was proportional to ALT activity. Utilizing a pyruvate standard curve 
(figure 2.3) the activity of ALT was calculated. To avoid false positive results a 
blank sample in which the substrates were omitted was run in parallel with the test 
samples. Subsequently, the background was corrected by subtracting the blank 
value from the test value.  
 
Figure 2. 3: Pyruvate standard curve which was used to measure the activity of alanine 
transaminase (ALT). ALT transfers an amino group from alanine to alpha-ketoglutarate producing 
pyruvate and glutamate. The concentration of pyruvate was measured colorimetrically at 570 nm 
wavelength using a microplate reader. 
 
 
y = 0.1389x - 0.0416
0
0.4
0.8
1.2
1.6
0 2 4 6 8 10 12
O
.D
. 5
70
Pyruvate nmol
2.  Materials and methods 
 
38 
 
 
2.2.4.2 Aspartate transaminase assay 
 
Aspartate transaminase (AST) was measured in plasma separated from heart 
blood in a colorimetric reaction using a commercially available kit according to the 
manufacturer’s instructions (Sigma-Aldrich Corp., St. Louis, MO, USA). AST 
catalyzes the conversion of alpha-ketoglutarate plus aspartate to oxaloacetate and 
glutamate. Glutamate was detected enzymatically in a reaction that converts a 
colorless probe into a color. The developed color was measured using a microplate 
reader at 450 nm wavelength. To avoid false positive results, a blank was included 
in which the substrates were omitted. Subsequently, the results of the blank was 
subtracted from the test samples. The activity of AST was calculated with the aid 
of a standard curve (figure 2.4) prepared from glutamate. 
 
 
 
Figure 2. 4: Glutamate standard curve which was used to measure the activity of aspartate 
transaminase (AST). AST catalyzes the conversion of alpha-ketoglutarate plus aspartate to 
oxaloacetate and glutamate. The concentration of glutamate was measured in a colorimetric 
reaction at 450 nm wavelength using a microplate reader. 
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2.2.5 Histopathology 
2.2.5.1 Hematoxylin and eosin staining 
 
Hematoxylin and eosin (H&E) staining was performed in five µm thick tissue 
sections prepared using a microtome (Microm, Walldorf, Germany). In order to 
remove paraffin the sections were warmed up at 56-60◦ C for 30 min and then at 
65-70◦ C until melting of paraffin. This was followed by incubation three times, 5 
min each, in xylene. The sections were then rehydrated by incubation in a 
descending ethanol gradient (98%, 95%, 90%, 80% and 70%) for 5 min each. After 
washing for 5 min in distilled water the sections were incubated for 5 min in Mayer’s 
hematoxylin (1:5) (Merk, Darmstadt, Germany). The excess hematoxylin was 
removed by washing under running tap water for 15 min. Subsequently, incubation 
in eosin (1%) was done for 3 min followed by a breif rinsing in distilled water. 
Afterward, the sections were dehydrated by incubation in an ascending ethanol 
series (70%, 80% and 90%) for 5 seconds each and then two-times in absolute 
ethanol 5 min each. Subsequently,  the sections were incubated for 3 min in xylene 
and then mounted with entellan for preservation. Images were acquired with a 
brightfield microscope using Cell F software (Olympus, Hamburg, Germany). 
 
2.2.5.2 Picrosirius red staining 
In order to visualize collagen deposition in fibrosis picrosirius red staining was 
performed using a commercially available kit according to the manufacturer’s 
instructions (Polyscience Europe GmbH, Eppelheim, Germany). The staining was 
performed in five µm thick paraffin embedded tissue sections. The sections were 
incubated in xylene two-times 5 min each. After deparaffinization, the sections 
were rehydrated in 100% and 95% ethanol 5 min each then in 70% and 50% 
ethanol 2 min each. Afterward, the tissue sections were rinsed breifly in distilled 
water for 2 min. Subsequently, the sections were immersed in solution A 
(phosphomolybdic acid) for 2 min followed by rinsing shortly in distilled water for 
90 seconds. Afterward, the sections were immersed in solution B ( picrosirius red 
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F3BA) for 1 hour followed by washing in distilled water for 2 min. Subsequently, 
the sections were placed in solution C ( 0.01% HCl) for 2 min. Afterward, the 
sections were dehydrated in a graded ethanol series (70%, 95% and 100%), 2 min 
each and then incubated in Roti-histol for 3 min. Finally, the sections were 
preserved by mounting with entellan. Images were acquired with a brightfield 
microscope using Cell F software (Olympus, Hamburg, Germany). 
 
2.2.6 Glutathione assay  
GSH and GSSG were measured based on the method of New and Chan 2008. 
GSH was derivatized with N-ethylmaleimide (NEM) to prevent oxidation of the 
sulfhydryl group and GSSG remained unchanged. For the GSH two isomers are 
formed. A buffered NEM solution was added immediately to the weighed liver 
sample. After homogenization the protein was precipitated by trichloroacetic acid. 
Lipophilic compounds were extracted by dichloromethane. The GSH-NEM 
derivatives and GSSG fraction was evaporated to dryness under a stream of 
nitrogen. The residue was reconstituted in water and then analyzed by LC-MS/MS. 
The analytes were separated on a PolarTec (125 x 3 mm, 3µm) column with a 
corresponding precolumn at 30 °C. The mobile phase was formed of formic acid 
in water (0.1 %) and formic acid in acetonitrile / water (0.1 %; 80 %/ 20 %) and was 
applied as gradient with a flow rate of 0.2 mL/min. The retention times were for 
GSSG 8.9 min and for the two GSH-NEM isomers 11.8 and 13.6 min. The 
detection was operated in the multiple reaction monitoring (MRM) mode with 433 
-> 304 (quantifier) and 433 -> 201 (qualifier) for the GSH-NEM derivatives and 613 
-> 355 (quantifier) and 613 -> 484 (qualifier) for the GSSG. The signals of the two 
GSH derivatives were added for the quantification. 
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2.2.7 Measurement of acetaminophen and its metabolites 
 
Acetaminophen and its metabolites were measured in blood plasma collected from 
the portal vein, the liver vein as well as the mixed venous blood in the right heart 
chamber. The analysis was done using LC-MS/MS technique in cooperation with 
Dr. Martin Vonbergen, proteomics department, Helmholtz Centre For 
Environmental Research, Leipzig, Germany. 
 
2.2.8 Immunohistochemistry 
 
2.2.8.1 Immunoperoxidase staining 
 
Immunoperoxidase staining was performed on five µm thick paraffin or frozen 
tissue sections. In order to prepare the paraffin sections for staining, 
deparaffinization and rehydration steps were done as described above. 
Subsequently, antigen retreival was performed by boiling three times, 5 min each, 
in either citrate (pH 6.0) or tris/EDTA (pH 9.0) buffer according to the type of 
antibody (table 2.2). The sections were allowed to cool down for 30 min and then 
washed in distilled water for 5 min before proceeding to the next step. 
Subsequently, the  endogenous peroxidases were blocked by immersion of the 
sections in 0.3% hydrogen peroxide in methanol for 15 min. Afterward, the sections 
were washed briefly in distilled water and then two times, 10 min each, in TBS. 
In order to prepare the frozen liver tissue for staining, five µm thick sections were 
performed using a Leica CM 3050s-cryostate (Leica Microsystems, Wetzlar, 
Germany). The sections were fixed in 3% PFA for 5 min at 4◦ C followed by washing 
in PBS for 5 min. Subsequantly, the sections were incubated in an ascending 
methanol series (50%, 70% and 90% for 1 min each). To avoid the possible 
interference of endogenous peroxidases, the sections were immersed in 0.3% 
hydrogen peroxide in methanol for 15 min. Subsequently, the sections were 
incubated in a descending methanol series (90%, 70% and 50% for 1 min each) 
and then washed in PBS for 5 min. 
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Afterward, the paraffin as well as th cryo sections were processed in the same 
way. In order to avoid the non-specific bindings of the antibodies, the sections were 
incubated in BSA/PBS solution for 2 h. Furthermore, the endogenous avidin and 
biotin were blocked using a commercially avilable kit according to the 
manufacturer’s instructions (Vector laboratories, Burlingame, USA). Subsequently, 
the sections were incubated overnight with the primary antibody (table 2.2) in a 
humid chamber at 4◦ C. Subsequently, the sections were washed in TBST three 
times, 5 min each. The sections were further incubated in BSA/PBS solution for 2 
h. Subsequently, the sections were incubated with an apropriate seconday 
antibody (table 2.2) for 2 h in a humid chamber at room teprature followed by 
washing in TBST for three times 5 min each. In case of using un conjugated 
secondary antibodies, the tissue sections were further incubated with streptavidine 
HRP for 1 h in a humid chamber at room teprature followed by washing three times 
in TBST 5 min each. Finally, the antibodies binding were visualized by incubation 
in either DAB or AEC substrate. In case of using DAB substrate, the sections were 
pre-immersed in tris-HCL solution for 5 min and then stained with DAB solution for 
4-7 min according to the color development. In case of using AEC substrate, the 
sections were placed in citrate buffer for 5 min and then stained with AEC for 5-10 
min according to the color development. Subsequently, the sections were washed 
in TBS for 2 min. In order to visualize the nucleus, a counter staining with Mayer’s 
hematoxylin was done for 1 min followed by washing under running tap water for 
10 min. The AEC stained sections were then preserved by mounting with an 
aqueous mounting media. The DAB stained sections were dehydrated by 
incubation in an ascending ethanol series (70%, 90%, 95% and 100%, for 30 
seconds each). Furthermore, the sections were washed in rotihistol for 4 min. The 
sections were then preserved by mounting with entellan. Images from the stained 
sections were acquired with a fluorescence microscope BX41 using Cell F software 
(Olympus, Hamburg, Germany). 
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Table 2. 2: Used antibodies and staining conditions 
Target 
Tissue 
section 
Retreival 
reagent 
Primary antibody Secondary antibody 
Antibody Concentation Antibody Concentration 
B-cell FFPE Citrate 
Rat anti- 
B220 
1:1000 
rabbit 
anti-rat 
IgG 
1:1000 
Proliferation FFPE Citrate 
Rat anti-
BrdU 
1:25 
rabbit 
anti-rat 
IgG 
1:1000 
T-cell Frozen - 
Rabbit 
anti-CD3 
1:50 
HRP anti rabbit        
(envision rabbit kit) 
Leukocytes FFPE Citrate 
Rat anti-
CD45 
1:400 
rabbit 
anti-rat 
IgG 
1:1000 
CYP2E1 Frozen - 
Rabbit 
anti-
CYP2E1 
1:250 
Swine 
anti-rabbit 
1:20 
HSCs FFPE Citrate 
Rabbit 
anti-
desmin 
1:400 
Swine 
anti-rabbit 
1:20 
HSCs Frozen - 
Rabbit 
anti-
desmin 
1:400 
donkey 
anti-rabbit 
Cy3 
1:100 
 
Macrophage 
 
FFPE 
 
Citrate 
 
Rat anti-
F4/80 
 
1:50 
rabbit 
anti-rat 
IgG 
 
1:1000 
Neutrophils FFPE Citrate 
Rat anti- 
LY6G 
1:5000 
rabbit 
anti-rat 
IgG 
1:1000 
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Activated 
HSCs 
FFPE Tris/EDTA 
Mouse 
anti 
human α-
SMA 
(Dako) 
1:100 
HRP anti mouse        
(envision mouse kit) 
Activated 
HSCs 
FFPE Citrate 
Mouse 
anti  α-
SMA 
(Abcam) 
1:50 
MaxFluor 
488 
(mouse 
on mouse 
kit) 
1:100 
Activated 
HSCs 
FFPE Citrate 
Rabbit anti 
α-SMA 
(Abcam) 
1:50 
donkey 
anti-rabbit 
Cy3 
1:100 
 
2.2.8.2 Immunofluorescence staining : co-staining of α-SMA and desmin 
 
In order to visualize the acivated and quiescent HSCs, immunofluorescence 
staining was performed in formalin fixed paraffin embedded (FFPE) tissue sections 
using antibodies against α-SMA and desmin. The deparaffinization, the 
rehydration as well as the antigen retrieval steps were performed as described 
above. Since the used anti-α-SMA antibody was raised in mouse, a mouse on 
mouse kit (MaxVision Biosciences, Dianova, Hamburg, Germany) was used 
according to the manufacturer’s instructions to avoid non-specific bindings. Breifly, 
the sections were incubated with a protein blocking solution for 10 min to prevent 
the non-specific background. Subsequently, a blocking reagent was applied for 1 
h in order to bind the endogenous immunoglobulins. After a brief rinsing in PBS, 
the sections were incubated overnight with mouse monoclonal anti-α-SMA 
antibody, 1:50 (Abcam, Cambridge, UK) (table 2.2) in a humid chamber at 4◦ C. 
The sections were then washed three times in PBS for 2 min each. Subsequantly, 
the sections were incubated with a secondary antibody conjugated to MaxFlour 
488 (MaxVision Biosciences, Dianova, Hamburg, Germany) for 1 h in a dark humid 
chamber followed by three times washing in PBS.  
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Before proceeding to the next step, the sections were incubated for 1 h in 3% BSA, 
3% tween 80 in PBS in order to block the non-specific bindings. Subsequently, the 
sections were incubated with anti-desmin antibody, 1:400 (Thermo Scientific, 
Braunschweig, Germany) in a humid chamber overnight at 4◦ C. After washing 
three times in PBS, a secondary antibody was added: Cy3 affinipure F(ab)2 
fragment donkey anti-rabbit IgG (H+L), 1:100 for 2 h in a dark humid chamber at 
room temprature. In order to remove the excess antibody, the sections were 
washed three times, 5 min each, in PBS. Subsequently, nuclear visualization was 
done by counter staining with DAPI for 4-5 min followed by rinsing three times, 5 
min each, in PBS and washing in distilled water for 10 min. Finally, the slides were 
mounted with anti-fading mounting media. The staining was visualized by using a 
confocal laser scanning microscope (Olympus BX61 microscope, Hamburg, 
Germany) using Olympus Fluoview version 4.0 b software. 
 
2.2.8.3 Co-staining of liver macrophages and activated stellate cells 
 
Co-staining of liver micro-architecture and macrohages as well as activated HSCs 
was done in 75 µm thick liver slices prepared using a vibratome (Leica 
Microsystems, Wetzlar, Germany). The prepared slices were placed in 24 well 
plates and washed for three times, 10 min each, in PBS. Subsequently, antigen 
demasking was performed by addition of 2 ml citrate buffer and cooking for 11 min 
in a steam cooker. After washing three times in PBS, the slices were immersed in 
a blocking serum (3% BSA, 3% tween 80 in PBS) for 2 h at room temperature on 
a shaker. Afterward, the slices were incubated with the primary antibodies: rabbit 
anti-α-SMA (1:100, Abcam, Cambridge, UK) and rat anti-F4/80 (1:25, AbD 
Serotec, Bio-Rad, Puchheim, Germany). The incubation was done at 4◦ C 
overnight with shaking. Subsequently, the excess antibodies were removed by 
washing three times, 10 min each, in PBS with shaking. The slices were then 
further immersed in the blocking serum (3% BSA, 3% tween 80 in PBS) for 1 h at 
room temperature on a shaker. Subsequently, the slices were incubated with the 
secondary antibodies: alexa fluor 647 affinipure F(ab)2 fragment donkey anti-rat 
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IgG (H+L) (1:50, Dianova, Hamburg, Germany), and Cy3 affinipure F(ab)2 
fragment donkey anti-rabbit IgG (H+L) (1:100, Dianova, Hamburg, Germany); the 
incubation was done for overnight at 4◦ C on a shaker. Following washing steps, 
the slices were again incubated with the blocking serum for 2 h at room 
temperature with shaking. Subsequently, the tissue slices were incubated with 
goat anti-mouse DPPIV/CD26 ectodomain (1:100, R&D system, Minneapolis, MN, 
USA) for overnight at 4◦ C with shaking. Afterward, the slices were then washed 
three times, 10 min each, in PBS with shaking. The slices were then incubated 
with donkey F(ab)2 anti-goat IgG (H+L)-alexa fluor 488 antibody (1:100, Dianova, 
Hamburg, Germany) overnight at 4◦ C with shaking. After washing three times in 
PBS, the slices were counter stained with DAPI for 90 min in order to visualize the 
nucleus. Subsequently, the slices were washed three times, 10 min each, on PBS 
and one time for 10 min in distilled water. Finally, the slices were mounted on 
microscopic slides using fluor-preserve reagent and allowed to dry in dark. Images 
were acquired using a confocal microscope.  
 
2.2.9 TUNEL staining 
 
2.2.9.1 Colorimetric TUNEL staining 
 
In order to visualize DNA breaks and cell death, TUNEL staining was performed 
using a commercially available kit according to the manufacturer’s instructions 
(Promega, Mannheim, Germany). The staining was done in five µm FFPE tissue 
sections. Following deparaffinization and rehydration, the sections were immersed 
in 4% PFA for 15 min and then washed twice in PBS for 5 min. Subsequently, the 
tissue was permeabilized by covering with proteinase K solution (20 µg/ml) for 10 
min at room temperature. After washing in PBS for 5 min, samples fixation was 
repeated by immersion in 4% PFA for 5 min. The sections were washed twice in 
PBS, 5 min each, and then covered with equilibration buffer for 8 min at room 
temperature. Subsequently, the sections were incubated with TdT reaction mix 
(equilibration buffer 98 µl, biotinylated nucleotide mix 1 µl and rTdT enzyme 1 µl 
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for each individual section) and covered with a plastic cover slips for 1 h at 37◦ C 
in a humid chamber. The reaction was stopped by washing in 2X SSC buffer for 
15 min. Subsequently, the sections were immersed three times, 5 min each, in 
0.5% BSA, 0.1 triton X-100 in PBS on a shaker followed by washing in PBS for 5 
min. The endogenous peroxidases were blocked by immersion in 0.3% hydrogen 
peroxide for 3-5 min. After washing three times in PBS. The sections were 
incubated with streptavidin HRP (1:500) for 30 min at room temperature in a humid 
chamber followed by washing three times in PBS. TUNEL positive signal was 
visualized by covering the sections with DAB solution for 3-5 min followed by 
washing in distilled water for 5 min. Subsequently, the sections were immersed in 
Mayer’s hematoxylin for 60-90 seconds. The excess hematoxylin was removed by 
washing under running tap water for 10 min. Finally, the tissue sections were 
dehydrated and preserved by mounting with entellan. Images were acquired with 
a brightfield microscope using Cell F software (Olympus, Hamburg, Germany). 
 
2.2.9.2 Combined staining of TUNEL, α-SMA and F4/80 
 
Co-staining of TUNEL, α-SMA and F4/80 was done in four µm FFPE tissue 
sections. Initially, the sections were stained with TUNEL as described above with 
three exceptions: (1) a fluorometric TUNEL kit was used (Promega, Mannheim, 
Germany), (2) the permeabilization step using proteinase K was omitted as it 
interfere with the follow up staining, and (3) the 4% PFA should be methanol free. 
As a positive control for DNA fragmentation, DNase I was added to an APAP 
treated liver tissue sections on day three directly before adding equilibration buffer 
according to the manufacturer’s instructions (Promega, Mannheim, Germany) and 
processed in the same way as the test tissue sections. After TUNEL staining the 
sections were further prepared for immunostaining. First, antigen retrieval was 
done by immersion in citrate buffer for 15 min in a water bath at 70◦ C. The tissue 
sections were allowed to cool down for 20 min and then washed 3 times in PBS. 
To avoid non-specific staining, the tissue sections were incubated with 3% BSA, 
3% tween 80 in PBS for 1 h at room temperature in a humid chamber. 
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Subsequently, the sections were incubated with the primary antibodies: rabbit anti-
α-SMA (1:50, Abcam, Cambridge, UK) and rat anti-F4/80 (1:25, AbD Serotec, Bio-
Rad, Puchheim, Germany), overnight at 4 C◦ in a humid chamber. After washing 
in PBS, the sections were immersed in a blocking serum (5% donkey serum, 3% 
tween 80 in PBS) for 1 h at room temperature. Subsequently, the tissue sections 
were incubated with the secondary antibodies: alexa fluor 647 affinipure F(ab)2 
fragment donkey anti-rat IgG (H+L) (1:100, Dianova, Hamburg, Germany) and Cy3 
affinipure F(ab)2 fragment donkey anti-rabbit IgG (H+L) (1:100, Dianova, 
Hamburg, Germany) for 1 h at room temperature in a humid chamber. After 
washing in PBS, counter staining with DAPI was performed followed by washing 
three times in PBS and one time in distilled water for 10 min. The tissue sections 
were preserved by mounting with fluor-preserve reagent. The staining was 
visualized by a confocal laser scanning microscope (Olympus BX61 microscope, 
Hamburg, Germany) using Olympus Fluoview version 4.0 b software. 
 
2.2.9.3 Combined staining of TUNEL and desmin 
 
Combination of TUNEL and desmin was perofrmed in 4 or 30 µm frozen tissue 
sections as indicated in the results section. First, TUNEL staining was performed 
using a commercially available fluorometric TUNEL kit (Promega, Mannheim, 
Germany) according to the manufacturer’s instructions with the exception of 
omitting the permeabilization with proteinase K step. Subsequently, the sections 
were prepared for desmin immunostaining by immersion in a blocking serum (3% 
BSA, 3% tween 80) in PBS for 1 h at room temperature. Afterward, the tissue 
sections were incubated with rabbit anti-desmin antibody (1:400, Thermo 
Scientific, Braunschweig, Germany) overnight at 4◦ C in a humid chamber. After 
washing three times in PBS, the sections were incubated with Cy3 affinipure 
F(ab)2 fragment donkey anti-rabbit IgG (H+L) (1:100, Dianova, Hamburg, 
Germany) for 2 h at room temperature in a humid chamber. Subsequently, the 
tissue sections were washed three times in PBS. In order to visualize the nucleus, 
counter staining with DAPI was performed followed by washing three times in PBS 
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and one time in distilled water for 10 min. Finally, the tissue sections were mounted 
with fluor-preserve reagent and allowed to dry at room temperature. The staining 
was imaged with a confocal laser scanning microscope. 
 
2.2.10 Intravital imaging 
In vivo imaging of intact mice livers was done using a custom modified inverted 
LSM-MP7 (Zeiss, Jena, Germany) according to the method of Reif et al. (2017). 
Briefly, at the indicated time period, fluorescently labelled antibodies and 
fluorescent markers were administered via the tail vein (table 3.2). Subsequently, 
the mice were anesthetized with an i.p. injection of ketamine (64 mg/kg), xzylazine 
(7.2 mg/kg) and acepromazine (1.7 mg/kg). In order to expose the liver for intravital 
imaging, a small window was made below the xiphoid process. After cutting of the 
falciform ligament, the left liver lobe was exposed by gently pushing of the 
abdomen and placed on 0.17 mm thick cover slip (Ocon 159, Logitech, Glasgow, 
UK) and the mouse placed on a lateral position. The exposed liver was then placed 
at the microscope stage using a custom-made platform and covered with saline 
soaked gauze. The quality of mouse preparation was controlled by the regular 
blood flow at the observed region. 
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Table 2. 3: Fluorescent marker dyes and antibodies used for in vivo imaging. 
 
Marker Indicated structure Source Dose  
Application 
volume  
Rhodamine 123 
Mitochondrial 
membrane potential 
and liver morphology 
Thermo Scientific, 
MA, USA  
0.8 mg/kg 
20 µl in 
PBS/methanol 
Hoechst 33258 Nuclei 
Thermo Scientific, 
MA, USA 
5 mg/kg 20 µl in PBS 
PE-labelled 
CD11b 
Infiltrating 
macrophages 
eBioscience, CA, 
USA 
60 µg/kg 100 µl in PBS 
PE-labelled 
NK1.1 
NK cells and innate 
lymphoid cells 
eBioscience, CA, 
USA 
60 µg/kg 100 µl in PBS 
PE-labelled 
F4/80 
Resident and infiltrating 
macrophages 
eBioscience, CA, 
USA 
60 µg/kg 100 µl in PBS 
 
 
2.2.11 Flow cytometric analysis of intrahepatic leukocytes 
 
Livers of untreated, APAP plus saline and APAP plus clodronate treated mice were 
perfused in vivo via the portal vein with 10 ml 1x PBS and excised. 
Homogenization of liver tissue was performed using liver disassociation kit 
(Miltenyi Biotec, Bergisch Gladbach, Germany) and gentle MACS Octo Dissociator 
according to the manufacturer’s instructions. Digested and minced livers were 
subsequently passed through a meshed screen and washed in DPBS. After 
centrifugation, the supernatant was removed and the remaining pellet was 
resuspended in 36% Percoll solution and subjected to density gradient 
centrifugation at 1,000 x g for 15 minutes at 20°C. Pelleted leukocyte-solution was 
washed, subsequently red cells were lysed with Red Cell Lysing Buffer (ACK) for 
5 minutes at room temperature. Lysis was neutralized by addition of 1x PBS and 
centrifuged. After centrifugation, the resulting liver leukocyte-enriched pellet was 
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resuspended in full medium and counted with tryptan blue in Neubauer chamber 
hemocytometer. In the next step, cells were Fc-blocked followed by a surface 
staining 10 minutes at room temperature with the following battery of antibodies 
(all from BioLegend) raised against: CD45 (1:400), CD11c (1:25), NK1.1 (1:25), 
CD3 (1:50), CD4 (1:800), CD8 (1:800), CD19 (1:50) including also markers for 
dead cells (Zombie Dye Red, BioLegend). After debris and doublets are excluded, 
isolated liver leukocytes were detected as viable (Zombie red negative) CD45-
positive cells and further sub-gated where dendritic cells, NK cells, NKT cells, T 
helper, cytotoxic T as well as B cells can be differentiated. By inclusion of counting 
beads (123 count eBeads, eBioscences) into the analyzed cell suspension besides 
percentages of the individual cell fractions also the total numbers of cells were 
determined. Flow cytometric analysis was performed on a LSR Fortessa (BD) and 
analyzed with FlowJo (Tree Star). 
 
2.2.12 Statistical analysis 
 
Statistical analysis was done using SPSS software, version 22, with one-way 
ANOVA pairwise comparisons by Turkey’s test. In case of unequal variances, 
Independent-samples T-test was performed. P<0.05 was considered statistically 
significant. 
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3. Results 
 
3.1 Acetaminophen-induced liver injury 
 
3.1.1 Factors influencing acetaminophen-induced hepatotoxicity 
 
In order to identify the ideal settings for the follow up experiments some basic parameters 
had to be tested. The goal of these experiments was to understand modifying factors of 
acetaminophen (APAP)-induced liver injury. First, the influence of fasting was studied. 
For this purpose, a single high dose of APAP (450 mg/kg) was injected i.p. to a group of 
either ad libitum fed or overnight fasted mice. Blood as well as liver tissue samples were 
collected on day 1 after APAP administration (figure 3.1A). Fasted mice showed marked 
elevation of transaminase enzymes compared to fed mice (figure 3.1B). In order to 
visualize APAP-induced hepatic damage, formalin fixed paraffin embedded liver tissue 
sections were stained with hematoxylin and eosin (H&E). Microscopically, pericentral liver 
damage was observed in the fasted mice, whereas individual sporadic dead hepatocytes 
were detected in the pericentral compartment of the liver lobule of the fed mice (figure 
3.1C). Together, these data show that fasted mice are more sensitive to APAP-induced 
liver injury.  
In order to find the reasons why fasted mice are more sensitive to APAP, liver tissue 
sections were immunostained using antibodies against CYP2E1, the main enzyme 
catalyzes the metabolic activation of APAP to the toxic metabolite N-acetyl-p-
benzoquinone imine (NAPQI). In addition, pieces of frozen liver tissues were analyzed for 
glutathione (GSH) content which is a scavenger for NAPQI. CYP2E1 staining showed no 
difference between fasted and fed mice (figure 3.2A). In contrast, fasted mice showed 
decreased levels of both reduced (GSH) as well as oxidized (GSSG) glutathione (figure 
3.2B). In conclusion, fasted mice are more sensitive to APAP toxicity perhaps due to 
depletion of GSH. 
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Figure 3. 1: Fasted mice are more sensitive to acetaminophen (APAP) than fed mice. (A) Experimental 
design: overnight fasted or ad libitum fed mice received a single dose of 450 mg/kg APAP. 24 h later, heart 
blood as well as liver tissue samples were collected. (B) Higher transaminases [alanine transaminase (ALT) 
and aspartate transaminase (AST)] activity in fasted compared to fed mice after APAP treatment. (C) 
Hematoxylin and eosin (H&E) staining showing pericentral liver injury in fasted mice on day one after APAP 
intoxication. Scale bars: 100 µm. ***p<0.001, **p<0.01 when compared to the fed mice group. 
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Figure 3. 2: Lower levels of glutathione in the liver tissue of fasted mice. (A) Immunostaining of liver 
tissue sections using antibodies against CYP2E1 showing normal pericentral zonation of CYP2E1 both in 
fed as well as fasted mice. Scale bars: 200 µm. (B) Lower levels of reduced (GSH) as well as oxidized 
(GSSG) glutathione in the liver tissue of fasted mice compared to ad libitum fed mice. **p<0.01 when 
compared to the fed mice group. 
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3.1.2 Pharmacokinetics of acetaminophen overdose 
 
In order to get a deeper insights about APAP pharmacokinetics, a kinetic experiment was 
performed in which a single dose of 450 mg/kg APAP was injected i.p. Blood as well as 
liver tissue samples were collected as early as 5 min up to 8h after APAP administration 
(figure 3.3). Blood samples were collected from the portal vein (representing liver inflow), 
the hepatic vein (representing liver outflow) and from the right heart chamber 
(representing mixed venous blood) and analyzed for the presence of APAP and its 
metabolites. The peak blood concentration of APAP was reached within 15 min after 
administration. This was associated with production of phase II products; glucuronide and 
sulfate metabolites, as well as glutathione and cysteine adducts (figure 3.4). The peak of 
metabolite formation occurred between 15 min and 1h after APAP injection. The blood 
became almost completely free from both APAP and its metabolites at the time between 
2 and 4h after APAP administration (figure 3.4).   
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 3: Pharmacokinetics of acetaminophen (APAP). Experimental design: male C57BL/6N mice 
received a single dose of APAP (450 mg/kg) intraperitoneally. Liver tissue samples as well as blood from 
the portal vein, the hepatic vein and the right heart chamber were collected in a time dependent manner 
after APAP administration. Three mice were scarified at each time point. 
 
3.  Results 
56 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 4: Pharmacokinetics of acetaminophen (APAP). Blood concentrations of APAP and its 
metabolites in mice at different time intervals after administration of 450 mg/kg APAP. In cases of APAP, 
APAP glucuronide and APAP sulfate absolute concentrations were calculated, while in cases of glutathione 
and cysteine adducts a relative quantification was done. Data are means ± SE of three mice per time point. 
***p<0.001, **p<0.01 when compared to the control (0) group. 
 
In the next step, the impact of acetaminophen intoxication on GSH levels was studied. 
For this purpose, GSH concentrations were measured in liver tissue as well as in blood 
collected from the kinetic experiment (figure 3.3). APAP administration lead to time-
dependent depletion of glutathione both in blood as well as in liver tissue (figure 3.5). The 
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lowest concentrations in the liver tissue were detected at the time between 1 and 4h after 
APAP injection and started to recover at 8h. In the next step, the influence of formation 
of the toxic metabolites of APAP and the depletion of glutathione on liver tissue 
morphology was studied. For this purpose, liver tissue sections were stained with TUNEL, 
as a marker of DNA breaks, and H&E. TUNEL positive staining was detected on the nuclei 
of the pericentral hepatocytes between 4 and 8h, especially at the inner pericentral 
hepatocytes (figure 3.6A). H&E staining showed pericentral liver damage at 4 and 8 h 
after injection of APAP (figure 3.6B). 
In conclusion, these results show that the metabolism of APAP occurs within the first 2h 
after injection which lead to depletion of glutathione and as a consequence pericentral 
liver injury develops within 4 till 8h after intoxication. 
 
 
 
 
 
 
 
Figure 3. 5: Impact of acetaminophen intoxication on liver and blood glutathione concentrations. 
Time dependent depletion of GSH and GSSG in liver tissue and blood collected from the portal vein, the 
hepatic vein and the right heart chamber. Data are means ± SE of three mice per time point. ***p<0.001, 
**p<0.01, *p<0.05 when compared to the corresponding control (0) group. 
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Figure 3. 6: Development of pericentral liver damage after acetaminophen intoxication (450 mg/kg). 
(A) TUNEL staining showing positive signals in the nuclei of the pericentral hepatocytes at 4 and 8h after 
injection. (B) H&E staining showing pericentral liver injury at 4 and 8h after APAP administration. Scale 
bars: 100 µm. 
 
3.1.3 Dose-dependent liver injury after APAP intoxication 
 
In order to find the ideal dose of APAP that can be later used to study liver injury and 
regeneration, a dose-dependent experiment was performed. For this purpose, various 
doses of APAP (between 50 and 500 mg/kg) were intraperitoneally injected to overnight 
fasted mice. 24h later, liver tissue samples were collected and prepared for H&E as well 
as CYP2E1 staining. Doses up to 89 mg/kg, failed to induce any detectable liver lesion 
(figure 3.7). In contrast, administration of 158 mg/kg lead to liver injury but only of a central 
fraction of the CYP2E1 positive area (figure 3.7). Whereas, after administration of 281 
mg/kg the entire CYP2E1 positive region of the liver lobule was destroyed. At doses 
higher than 375 mg/kg not only the CYP2E1 positive area was killed but also a fraction of 
the CYP2E1 negative region was damaged (figure 3.7). Moreover, severe liver 
hemorrhage was observed particularly after injection of 500 mg/kg (figure 3.8). In 
conclusion, doses between 200 and 300 mg/kg are sufficient to kill the pericentral 
hepatocytes and to study liver injury and regeneration after APAP intoxication.  
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Figure 3. 7: Relationship of 
CYP2E1 expression and 
APAP-induced liver injury. 
H&E staining showing dose 
dependent centrilobular liver 
damage. At very high doses 
(500 mg/kg) severe liver 
hemorrhage is also visible. 
CYP2E1 immunostaining 
showing the typical pericentral 
zonation of CYP2E1 in control 
liver. Administration of 158 
mg/kg APAP leads to killing of 
the central fraction of the 
CYP2E1 positive hepatocytes. 
Whereas, administration of 281 
mg/kg destroys the entire 
CYP2E1 positive hepatocytes. 
At higher doses, additionally a 
fraction of the CYP2E1 negative 
area is also killed. Scale bars: 
100 µm. 
3.  Results 
60 
 
 
 
Figure 3. 8: Liver lesion on day 1 after administration of very high doses of APAP. Injection of 281 
mg/kg APAP leads to killing of the pericentral hepatocytes. Whereas, administration of higher doses (500 
mg/kg) leads to additionally killing of a fraction of the periportal hepatocytes and severe liver hemorrhage. 
H&E staining, scale bars: 100 µm. 
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3.1.4 Liver injury and regeneration after acetaminophen intoxication 
 
In order to study liver injury and regeneration after APAP intoxication, a dose of 300 mg/kg 
was selected. Liver enzymes, histopathology as well as liver cell proliferation were 
analyzed in a time-resolved manner after APAP administration (figure 3.9A). 
Macroscopically, white spotted pattern of the liver was obvious as early as 6h after APAP 
administration and continued until day 2 (figure 3.9B). After day 4, the liver looked similar 
to controls. Microscopically, by H&E staining a restricted pericentral liver lobule damage 
was detected at the time between 6h and day 2 after intoxication (figure 3.10A). This was 
confirmed by elevation of transaminases (ALT and AST) at the same time period (figure 
3.10B). After day 4 the liver looked similar to controls and also enzyme activity returned 
to the basal level (figure 3.10). In the next step, 5-bromo-2'-deoxyuridine (BrdU) staining 
was performed in order to investigate, whether such efficient regeneration was a result of 
replacement proliferation of the surviving hepatocytes. For this purpose, a dose of 80 
mg/kg BrdU was administered i.p. 1h before liver collection (figure 3.9A). Subsequently, 
formalin fixed paraffin embedded liver tissue sections were immunostained using 
antibodies against BrdU. As expected, proliferation in healthy livers was rarely detected. 
In contrast, two days after APAP administration massive hepatocytes proliferation was 
visible. The proliferating cells were homogenously distributed in the liver lobule with a 
slight preference to the border of the dead cell area (figure 3.11). In addition, small size 
BrdU positive nuclei were detected within the dead cell area which might be for non-
parenchymal cells. On day 4, less hepatocyte proliferation was detected, preferentially at 
the border of the remaining dead cell area (figure 3.11). In conclusion, intoxication with 
300 mg/kg APAP leads to pericentral liver injury with a maximum damage on day one. 
This stimulates replacement proliferation leading to full recovery of the dead cell area 
within a week after intoxication. 
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Figure 3. 9: Liver injury and regeneration after APAP intoxication. (A) Experimental design: male 
C57BL/6N mice were intoxicated with APAP (300 mg/kg i.p) after overnight fasting. Heart blood as well as 
liver tissue samples were collected in a time-resolved manner after APAP injection. One hour before liver 
collection the mice received 80 mg/kg BrdU i.p. Five mice were scarified at each time point. (B) Gross 
appearance of the liver after APAP intoxication. The liver shows white spotted pattern at the time between 
6h and day 2 after APAP injection. After day 4 the liver looks similar to controls. 
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Figure 3. 10: Liver injury and regeneration after APAP intoxication. (A) H&E staining showing 
pericentral liver lobule damage at the time between 6h and day 2 after APAP administration. Scale bars: 
100 µm. (B) Marked elevation of alanine (ALT) and aspartate (AST) transaminases activity, at the time 
between 6h and day 2 after APAP administration. The data are means ± SE of five mice. ***p<0.001 when 
compared to the control (0h) group. 
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Figure 3. 11: 5-Bromo-2-deoxyuridine (BrdU) staining showing proliferation of liver cells (brown) at 
different time intervals after intoxication with 300 mg/kg APAP. The peak of proliferation can be seen on 
day 2 after APAP administration. Scale bars: 100 µm. 
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3.1.5 Compromised liver regeneration after intoxication with very high doses of 
acetaminophen 
 
In order to investigate whether the regeneration process will be compromised after 
intoxication with very high doses of APAP, a dose of 450 mg/kg was injected i.p. using 
the same experimental setup shown in figure 3.9A. Approximately 60% of the mice died 
between days 2 and 3 after administration of such a high dose. Grossly, the liver of the 
dead mice showed obvious bleeding (figure 3.12A). By H&E staining, the livers showed 
severe haemorrhage (figure 3.12B). In addition, the dead cell area was not only restricted 
to the pericentral compartment of the liver lobule but also extended to the midzonal and 
fractions of the periportal area (figure 3.12B, C). The survivor mice showed compromised 
liver regeneration. Grossly, white spotted pattern of the liver was evident at the time 
between 6h and day 4 after intoxication (figure 3.13A). After day 6 most of the liver lobes 
looked similar to controls. However, some parts failed to regenerate and form scars 
(figure 3.13C). By H&E staining, the cetrilobular damage was visible at the time between 
6h and day 4 (figure 3.13B). This was confirmed by elevation of the transaminases 
enzymes activity in this time frame (figure 3.14). In addition, haemorrhage was also 
evident especially on day 2 after intoxication. After day 6, the liver looked similar to 
controls with the exception of some parts which failed to regenerate (figure 3.13C). 
In order to check whether hepatocytes proliferation was altered upon intoxication with 
such a high dose, BrdU staining was performed. The results showed compromised 
proliferation both from the spatial as well as the temporal point of view in comparison to 
proliferation after intoxication with 300 mg/kg. First, proliferation was delayed, started on 
day 4 after APAP administration (figure 3.15). Second, proliferation was mostly restricted 
to the pericentral compartment of the liver lobule. Furthermore, some proliferating 
hepatocytes were detached and appeared within the dead cell area (figure 3.15). In 
conclusion, intoxication with very high doses of APAP leads to high mortality rate and 
compromised liver regeneration for the survivors. 
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Figure 3. 12: Severe liver haemorrhage in mice died from acetaminophen overdose (450 mg/kg). (A) 
Gross pathology, (B) H&E staining. Scale bars: 100 µm. (C) Whole slide scan showing damage of 
approximately 80% of the liver parenchyma, which exceeds the territory of CYP2E1 positive area (D). 
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Figure 3. 13: Liver injury and regeneration after intoxication with 450 mg/kg APAP. (A) Gross 
pathology showing white spotted pattern started as early as 6h after APAP injection and remained evident 
up to day 4. 
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Figure 3.13 B, C: (B) H&E staining showing pericentral liver damage between 6h and day 4, and 
hemorrhage particularly on day 2 after APAP administration. Scale bars: 100 µm. After day 6, the liver 
looked normal with the exception of some parts which failed to regenerate and form scars (C). Scale bar: 
200 µm. 
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Figure 3. 14: Aspartate (AST) and alanine (ALT) transaminases activity in heart blood at different 
time periods after intoxication with 450 mg/kg APAP. The activity of both enzymes was markedly 
elevated at the time between 6h and day 2 after APAP administration. Data are means ± SE of three mice. 
**p<0.01, *p<0.05 when compared to the control (0h) group. 
 
Figure 3. 15: 5-Bromo-2-deoxyuridine (BrdU) immunostaining in mice liver tissue sections at 
different time intervals after intoxication with APAP (450 mg/kg). Hepatocytes proliferation (brown) can 
be seen on day 4 and mostly restricted to the pericentral compartment of the liver lobule. Scale bars: 100 
µm. 
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3.2 Immune cells infiltration following acetaminophen intoxication 
 
The goal of the next step was to identify infiltrating immune cells during the destruction 
and regeneration processes following APAP intoxication. For this purpose, 
immunostaining was performed in liver tissue sections collected at different time periods 
after administration of 300 mg/kg APAP using antibodies against CD45 ( pan leukocytes 
marker), LY6G (neutrophil marker), B220 (B cell marker), CD3 (T cell marker), and F4/80 
(macrophage marker). The healthy livers showed few CD45 positive cells distributed 
homogeneously in the liver lobule, perhaps representing the liver resident Kupffer cells 
(figure 3.16). In contrast, upon APAP intoxication massive immune cell infiltration into the 
pericentral area of the liver lobule was observed at the time between 6h and day 4 (figure 
3.16). After day 6 the liver appeared similar to the controls. In order to identify these 
infiltrating leukocytes, cell type specific antibodies were used. LY6G immunostaining 
revealed that the healthy liver were almost free from neutrophils. In contrast, neutrophils 
swarms were detected after APAP injection. The infiltration was mostly predominant 
during the destruction process between 6h and day 1 after APAP intoxication (figure 
3.17). During the regeneration process (between days 2 and 4), neutrophils were also 
present but to a relatively low extent. After day 6, neutrophils were rarely detected. B220 
and CD3 staining in healthy livers showed few scattered B and T cells, respectively. 
Following APAP intoxication, few infiltrating B and T cells were detected in the dead cell 
area during the destruction as well as the regeneration processes (figures 3.18 and 3.19). 
After day 4 the basal levels of B and T cells were visible in the liver similar as in controls. 
F4/80 staining showed the liver resident macrophages (Kupffer cells) distributed in the 
liver lobule with a slight preference to the midzonal area in controls (figure 3.20A). During 
the destruction process (6h till day 1 after APAP administration) more infiltrating 
macrophages were detected at the border of the dead cell area. Whereas, on day 4 after 
APAP injection, massive macrophages infiltration was detected at the pericentral 
compartment of the liver lobule (figure 3.20A). In order to differentiate between the 
resident kupffer cells and the infiltrating macrophages, a fluorescently labeled anti CD11b 
antiboby (expressed on the surface of infiltrating monocytes) was i.v. injected in healthy 
mice as well as on day 4 after APAP intoxication followed by intravital imaging of the liver 
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using two-photon microscopy. The liver resident macrophages (kupffer cells) showed 
F4/80 high CD11b low staining (figure 3.20B). In contrast, the infiltrating macrophages 
showed F4/80 high, CD11b high staining and massively present in the pericentral 
compartment of the liver lobule on day 4 after APAP challenge (figure 3.20B). 
In conclusion, immune cells present in the liver are highly altered after APAP intoxication 
with particularly high neutrophils infiltration during the destruction process and massive 
macrophages infiltration during the regeneration process. 
Figure 3. 16: CD45 immunostaining in mice livers showing leukocytes infiltration at different time 
intervals after injection of 300 mg/kg APAP. Scale bars: 50 µm. 
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Figure 3. 17: Immunostaining of liver tissue sections using antibodies against LY6G showing 
infiltration of neutrophils at different time intervals after administration of APAP (300 mg/kg). The peak of 
neutrophils infiltration appears between 12h and day 1 after APAP injection. Scale bars: 100 µm. 
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Figure 3. 18: B220 immunostaining in mice liver tissue sections at different time intervals after APAP 
intoxication (300 mg/kg). The staining shows very few infiltrating B cells into the dead cell area during 
liver injury and regeneration. Scale bars: 50 µm. 
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Figure 3. 19: CD3 immunostaining in mice liver tissue sections at different time intervals after APAP 
intoxication (300 mg/kg). The staining shows few infiltrating T cells into the dead cell area during liver 
injury and regeneration. Scale bars: 50 µm. 
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Figure 3. 20: Macrophages infiltration after APAP intoxication. (A) F4/80 immunostaining showing 
resident as well as infiltrating macrophages at different time intervals after APAP injection (300 mg/kg). The 
staining shows massive macrophages infiltration into the pericentral compartment of the liver lobule during 
liver regeneration (day 4). Scale bars: 100 µm. (B) Intravital imaging of macrophages in healthy liver as well 
as on day 4 after APAP intoxication stained by fluorescently labeled anti-F4/80 (pan macrophages marker) 
or anti-CD11b (infiltrating macrophages marker) antibodies. The resident kupffer cells show F4/80 high, 
CD11b low staining. Whereas, the infiltrating macrophages show both high F4/80 as well as CD11b 
staining. Scale bars: 50 µm. 
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3.3 Hepatic stellate cells dynamics during liver injury and regeneration  
 
Due to the significant changes in the immune system of the liver which is known to interact 
with the non-parenchymal cells, the next chapter will focus on the state of HSCs during 
liver injury and regeneration. In order to distinguish activated and quiescent HSCs, liver 
tissue sections were collected at different time intervals after APAP intoxication (300 
mg/kg; see experimental design in figure 3.9A) and immunostained using antibodies 
against desmin (a marker of quiescent as well as activated HSCs) and alpha-smooth 
muscle actin (α-SMA; a marker of activated HSCs). As expected, HSCs are quiescent in 
healthy livers as indicated by desmin positive and α-SMA negative staining (figure 3.21). 
Whereas, the quiescent HSCs infiltrate the dead cell area on day one after APAP 
administration and get activated on day two as evidenced by α-SMA positive staining 
(figure 3.21). However, the number of activated HSCs was reduced by day four after 
APAP intoxication and completely cleared out by day six. Despite of massive killing of 
hepatocytes and HSCs activation this did not lead to liver fibrosis as evidenced by sirius 
red negative staining (figure 3.21). In order to confirm these interesting findings, similar 
experiments were performed using another model of liver injury in which a single dose of 
the hepatotoxic agent CCl4 (1.6 g/kg) was injected.  Similar  to APAP, CCl4 intoxication 
lead to massive killing of the pericentral hepatocytes (figure 3.22). This was followed by 
massive activation of HSCs particularly on day 2 which were completely eliminated by 
day 6 after CCl4 administration without fibrogenesis (figure 3.22). In conclusion, acute 
liver injury leads to transient massive activation of HSCs without fibrosis development. 
Since HSCs activation is known to be associated with fibrogenesis which contradicts with 
the current results, we decided to check HSCs activation in liver fibrosis under our 
experimental setup. For this purpose, C57BL/6N mice were treated repeatedly with CCl4 
(1 g/kg) twice a week for two months. Subsequently, liver tissue samples were collected 
in a time-resolved manner after the last injection (figure 3.23A) and analyzed for HSCs 
activation and fibrosis development. Repeated CCl4 administration lead to pericentral liver 
damage but less than that observed after an acute challenge (figure 3.23B, H&E). This 
was associated with moderate activation of HSCs (figure 3.23B, desmin and α-SMA), 
which also disappeared after day 6. However, in contrast to the acute situation, this 
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scenario lead to liver fibrosis as evidenced by positive sirius red staining (figure 3.23B) 
which persist upto day 10 after the last CCl4 injection. In conclusion, the data show that 
the presence of cell damage and the extent of stellate cells activation does not necessarily 
correlate with the degree of liver fibrosis.  
 
Figure 3. 21: No liver fibrosis despite of massive cell death and stellate cells activation after acute 
APAP challenge. The images show mice livers at different time intervals after intoxication with 300 mg/kg 
APAP. The panels show macroscopic appearance (grossly), microscopic appearance by hematoxylin and 
eosin staining (H&E), hepatic stellate cells (desmin), activated stellate cells (alpha-smooth muscle, α-SMA); 
scale bars: 100 µm, and sirius red staining as a marker of fibrosis; scale bars: 200 µm. 
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 Figure 3. 22: No liver fibrosis despite of massive cell death and stellate cells activation after acute 
CCl4 challenge. The images show mice livers at different time intervals after intoxication with 1.6 g/kg CCl4. 
The panels show macroscopic appearance (grossly), microscopic appearance by hematoxylin and eosin 
staining (H&E), hepatic stellate cells (desmin), activated stellate cells (alpha-smooth muscle, α-SMA); scale 
bars: 100 µm, and sirius red staining as a marker of fibrosis; scale bars: 200 µm. 
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Figure 3. 23: Moderate cell killing and activation of HSCs leads to liver fibrosis. (A) Experimental 
design of a fibrosis mouse model: male C57BL/6N mice were injected repeatedly with CCl4 (1g/kg, i.p.), 
twice a week for 2 months. Following the last dose of CCl4, the liver was harvested at different time periods 
(days 1, 3, 4, 6 and 10). Three mice were scarified at each time period. (B) Mice livers at different time 
intervals after the last dose CCl4.The panels show macroscopic appearance (grossly), microscopic 
appearance by hematoxylin and eosin staining (H&E), hepatic stellate cells (desmin), activated stellate cells 
(alpha-smooth muscle, α-SMA); Scale bars: 100 µm, and sirius red staining as a marker of fibrosis; scale 
bars: 200 µm. 
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3.4 Mechanisms of activated HSCs elimination 
 
For a deeper understanding of the fate of activated HSCs following acute and chronic 
liver injury, the mechanisms of elimination were studied in both damage scenarios. First, 
I checked whether the activated HSCs revert to the quiescent state. For this purpose, 
liver tissue sections were co-stained using antibodies against desmin and α-SMA. After 
repeated CCl4 administration, co-localization of desmin and α-SMA signals was visible on 
day 3 following the last dose of CCl4. In contrast, on day four, the signal of α-SMA 
markedly decreased despite of accumulation of HSCs on the pericentral area of the liver 
lobule as indicated by the positive desmin staining (figure 3.24A). Following an acute 
challenge with APAP, co-localization of desmin and α-SMA signals was also detected in 
the dead cell area at the time between days 2 and 4 after APAP administration (figure 
3.24B). However, after day 4 the signals of both α-SMA and desmin disappeared from 
the pericentral compartment and only the basal desmin positive HSCs appeared 
homogenously distributed in the liver lobule (figure 3.24B). These results show that 
reversion of activated HSCs to a quiescent phenotype could be a way of elimination of 
activated HSCs during fibrosis recovery but not during regeneration from an acute 
challenge. 
Second, the role of apoptosis in elimination of activated HSCs was studied. For this 
purpose, liver tissue sections were stained with TUNEL as a marker of DNA breaks. 
Significant TUNEL positive signal was detected in the fibrosis scenario, particularly on 
day 4 after the last CCl4 injection (figure 3.25A). The signals were mostly in HSCs as 
indicated by co-localization with desmin staining (figure 3.25A). In contrast, in case of 
APAP induced-acute liver injury TUNEL signal was not detectable during the regeneration 
phase (figure 3.25B). In order to confirm the negative results, a positive control sample 
was treated with DNase I on day 3 after APAP intoxication; the time when α-SMA signal 
reached to the peak. In addition, an early time point (8h after APAP injection) was also 
included; the time when killing of hepatocytes was active. Both conditions showed that 
the TUNEL staining worked properly also in activated hepatic stellate cells (figure 3.25 C, 
D). These results show that also apoptosis is not a relevant pathway for elimination of 
activated HSCs following acute liver injury. 
3.  Results 
81 
 
Third, the presence of macrophages and natural killer cells (NK) as main players involved 
in elimination of activated HSCs via induction of apoptosis (Radaeva et al. 2006; Tacke 
and Trautwein 2015; Tian et al. 2013) was investigated in both damage scenarios. In 
order to check the interaction of macrophages with HSCs, co-staining of liver tissue 
sections using antibodies against α-SMA and F4/80 was performed. The results showed 
massive macrophages infiltration during liver regeneration after acute as well as chronic 
injury (figure 3.26 A, B). To get a deeper insight after the acute damage scenario, confocal 
z-stacks imaging and 3-D reconstructions were performed at different time intervals 
following APAP intoxication. The results revealed massive infiltration of macrophages into 
the pericentral compartment and co-localization with HSCs on day 4 after APAP 
administration, the time when activated HSCs disappeared (figure 26 C).  
NK cells were visualized in vivo by two-photon microscopy after tail vein injection of NK1.1 
antibody. In contrast to macrophages, NK cell infiltration was observed only after repeated 
CCl4 intoxication (figure 3.26 D). In conclusion, although activated HSCs are eliminated 
both after acute and chronic liver damage scenarios, the responsible mechanisms seem 
to be different. 
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Figure 3. 24: Activated HSCs are eliminated by reversion to a quiescent phenotype during fibrosis recovery but not during 
regeneration from an acute challenge. Mice liver tissue sections were co-stained using fluorescently labeled antibodies against α-
SMA and desmin at different time periods after intoxication with either: (A) repeated CCl4 injection (1 g/kg); twice a week for 2 months, 
or (B) a single dose of APAP (300 mg/kg). The images show massive accumulation of desmin positive quiescent HSCs (α-SMA 
negative) in the pericentral compartment of the liver lobule during fibrosis recovery (day 4) but not during regeneration from an acute 
APAP challenge. Scale bars: 100 µm. 
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Figure 3. 25: Apoptosis is a relevant pathway for removal of activated HSCs during fibrosis recovery 
but not during regeneration from an acute challenge. (A) Positive TUNEL signal in activated HSCs 
during fibrosis recovery following repeated CCl4 intoxication (1 g/kg, twice a week for 2 months). Scale 
bars: 100 µm. (B) TUNEL staining at different time intervals after administration of a single dose of APAP 
300 mg/kg. The images show no apoptosis at the time when activated HSCs are eliminated (day 4). Scale 
bars: 100 µm. (C) Positive TUNEL signal in all liver cells after DNase I pre-treatment on day 3 after APAP 
intoxication. Scale bars: 50 µm. (D) Positive TUNEL signals in the pericentral hepatocytes at 8h after APAP 
intoxication (300 mg/kg). Scale bars: 100 µm. 
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Figure 3. 26: Macrophages and natural killer (NK) cells infiltration during liver recovery following an 
acute or chronic challenges. Alpha smooth actin (α-SMA) and F4/80 co-staining in mice livers at different 
time intervals after either: (A) repeated CCl4 (1 g/kg, twice a week for 2 months) or (B) single APAP (300 
mg/kg) administration. The images show massive macrophages infiltration at the time when activated 
stellate cells are eliminated. Scale bars: 100 µm.  
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Figure 3.26 C, D: (C) 3D reconstructions of confocal micrographs of liver tissue slices co-stained with 
antibodies against α-SMA (white) and F4/80 (red) at different time intervals after APAP intoxication. The 
images show activation of HSCs on day 2 after APAP administration. On day 4, massive infiltration of 
macrophages into the pericentral compartment of the liver lobule can be seen which frequently co-localize 
with α-SMA signal. Scale bars: 20 µm. (D) In vivo imaging of NK cells after i.v. injection of NK1.1 antibody 
in mice on day 4 following single APAP injection (300 mg/kg) or repeated CCl4 intoxication (1 g/kg, twice a 
week for 2 months). The liver morphology is visualized by i.v. injection of rhodamine 123 and the nuclei are 
visualized by i.v. injection of Hoechst 33258. The images show NK cells infiltration during fibrosis recovery 
(arrows) but not during regeneration from an acute challenge. The spleen of a healthy mouse serves as a 
positive control. Scale bars: 50 µm.  
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3.5 Role of macrophages in elimination of activated HSCs during liver 
regeneration  
 
From the results presented in the previous chapter, it seems that infiltrating macrophages 
are the main players in removal of activated HSCs following acute liver injury. To get a 
deeper insights about the role of macrophages in HSCs removal, a mouse system in 
which macrophages were depleted by administration of clodronate containing liposomes 
was used. In order to select the ideal time for macrophage depletion a preliminary 
experiment was performed in which clodronate was injected i.v. either before (one day), 
simultaneously with or after (day 1, 2 or 3) APAP administration (figure 3.27A). The liver 
tissue was collected on day 6 after APAP injection. The dead cell area was recovered in 
all treated groups as shown by H&E staining (figure 3.27B). The efficiency of clodronate 
in removal of macrophages was confirmed by the negative F4/80 staining (figure 3.27C). 
All clodronate treated mice showed a strong α-SMA signal compared to the saline treated 
group (figure 3.27D). However, removal of macrophages on day 2 after APAP injection 
lead to the highest α-SMA signal on day 6. In order to check whether macrophages are 
also important for activation of HSCs, an experiment was performed in which the mice 
were treated with clodronate one day before APAP administration and the activation state 
of HSCs was checked on day 2 after APAP injection (figure 3.28A). Clodronate treatment 
successfully removed all macrophages as evidenced by F4/80 negative staining (figure 
3.28B). Interestingly, the diameter of the dead cell area was less in clodronate treated 
mice (figure 3.28B). Moreover, the number of activated HSCs was strongly reduced 
following macrophage depletion (figure 3.28B). In conclusion, blocking of macrophages 
by clodronate affects both activation as well as removal of HSCs. Furthermore, 
administration of clodronate two days after APAP treatment is the most critical time for 
elimination of activated HSCs. 
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Figure 3. 27: 
Removal of 
macrophages is 
critical for 
elimination of 
activated HSCs. 
(A) Experimental 
design: mice 
received i.v. 
bolus injection of 
saline or 
clodronate 
containing 
liposomes (50 
mg/kg) either 
before, with or 
after APAP (300 
mg/kg) injection. 
(B) H&E staining 
on day 6 after 
APAP injection 
showing that the 
dead cell area is 
recovered in all 
treated groups. 
(C) F4/80 staining 
showing that 
clodronate 
treatment lead to 
efficient 
elimination of 
macrophages. 
(D) α-SMA 
staining on day 6 
after APAP 
injection showing 
massive 
presence of  
HSCs after 
macrophages 
depletion 
particularly if 
clodronate is 
given on day 2 
after APAP 
administration. 
Scale bars: 100 
µm. 
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Figure 3. 28: Role of macrophages during the destruction process after APAP injury. (A) Mice were 
injected i.v. with clodronate (50 mg/kg) or saline one day before APAP treatment (300 mg/kg) followed by 
liver collection on day 2 after APAP intoxication. (B) The images show that clodronate injection results in 
macrophages depletion (F4/80) which leads to less liver injury (H&E) and less stellate cells activation 
(desmin and α-SMA). Scale bars: 100 µm. 
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Before proceeding to the next step, another control experiment was performed in order 
to check whether clodronate treatment has a direct effect on HSCs. For this purpose a 
group of healthy mice were repeatedly injected with clodronate every 3 days followed by 
liver collection on day 8 (figure 3.29A). As expected, only quiescent HSCs homogenously 
distributed in the liver lobule were delectable as evidenced by desmin positive and α-SMA 
negative staining (figure 3.29B). F4/80 staining showed that clodronate treatment 
successfully depleted macrophages (figure 3.29B). 
 
 
 
 
 
 
Figure 3. 29: Clodronate administration has no direct effect on HSCs. (A) Mice were overnight fasted, 
two days later clodronate (50 mg/kg) was injected i.v. repeatedly every 3 days followed by liver collection 
on day 8. (B) F4/80 immunostaining showing that the liver is free from macrophages after clodronate 
treatment. Desmin staining shows the normal distribution of quiescent HSCs (α-SMA negative) in the liver 
lobule. Scale bars: 100 µm. 
 
Based on the results of the previous preliminary trials, an experiment was designed to 
study the role of macrophages in elimination of activated HSCs. APAP pretreated mice 
were injected repeatedly with clodronate containing liposomes every three days, started 
on day 2 after APAP injection. Liver tissue samples were collected on days 2, 4, 8, 12 
and 16 after APAP administration (figure 3.30A). As already shown in previous 
experiments, massive activation and infiltration of HSCs into the dead cell area was 
observed on day 2 after APAP injection (figure 3.30B). 
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Clodronate treatment lead to efficient macrophage depletion at all tested time periods as 
shown by F4/80 negative staining (figure 3.31). In contrast, in saline treated mice, 
massive macrophage infiltration into the pericentral compartment of the liver lobule was 
detected on day 4 after APAP administration (figure 3.31). However, both saline as well 
as clodronate treated mice showed efficient recovery of the dead cell area between days 
4 and 8 after APAP intoxication (figure 3.32). In order to investigate the impact of 
macrophages depletion on HSCs elimination, liver tissue sections were immunostained 
using antibodies against desmin as well as α-SMA. A very low number of activated HSCs 
was detected on day 4 after APAP administration in the saline treated mice and 
completely disappeared by day 8 (figures 3.33 and 3.34). In contrast, massive presence 
of activated HSCs in the pericentral compartment was detected in the clodronate treated 
mice on day 4 after APAP administration (figures 3.33 and 3.34). This was associated 
with slight deposition of ECM particularly on days 4 and 8 after APAP intoxication (figure 
3.34). However, this effect was transient and the activated HSCs as well as ECM were 
slowly eliminated between days 8 and 12 after APAP injection (figures 3.33 and 3.34). In 
conclusion, removal of macrophages leads to delayed elimination of HSCs after APAP-
induced acute liver injury. 
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Figure 3. 30: Depletion of restorative macrophages after injection of 300 mg/kg APAP. (A) 
Experimental design: mice received APAP (300mg/kg). Two days later, the mice were injected with 
clodronate (50 mg/kg) repeatedly every 3 days. The livers of 3 mice were collected on days 2, 4, 8, 12 and 
16 after APAP administration. (B) Day 2 after APAP intoxication showing massive activation (desmin, α-
SMA) and infiltration of HSCs into the dead cell area (H&E). Scale bars: 100 µm. 
 
 
 
 
Figure 3. 31: F4/80 immunostaining of liver tissue sections at different time intervals after treatment 
with APAP ± clodronate. The images show that clodronate treatment leads to efficient depletion of 
macrophages. Scale bars: 100 µm. 
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Figure 3. 32: Hematoxylin and eosin staining of liver tissue sections at different time intervals after 
treatment with APAP ± clodronate. The images show that clodronate treatment has no influence on the 
recovery of the dead cell area. The dead cell area is restored both in saline as well as clodronate treated 
mice. Scale bars: 100 µm. 
 
 
 
 
 
Figure 3. 33: Desmin immunostaining in liver tissue sections at different time intervals after 
treatment with APAP ± clodronate. Depletion of macrophages by clodronate treatment leads to prolonged 
accumulation of HSCs in the pericentral area of the liver lobule. Scale bars: 100 µm. 
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Figure 3. 34: Alpha smooth muscle actin and picrosirius red staining of mouse liver tissue sections 
at different time intervals after treatment with APAP ± clodronate. Macrophages depletion by 
clodronate leads to prolonged presence of activated HSCs and slight deposition of extracellular matrix 
(ECM) in the pericentral compartment of the liver lobule. However, both activated as well as ECM disappear 
slowly between days 4 and 16. Scale bars: 100 µm. 
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3.6 Identification of backup mechanisms for elimination of activated HSCs 
 
In the next step, the mechanism of elimination of activated HSCs in the absence of 
macrophages was investigated. First, we checked whether there was a reversion of 
activated HSCs to a quiescent phenotype. For this purpose, liver tissue sections from 
both saline as well as clodronate treated mice were co-stained using antibodies against 
desmin and α-SMA. As shown in previous experiments, low numbers of activated HSCs 
were detected in the pericentral compartment of the liver lobule on day 4 after APAP 
injection (α-SMA positive, desmin positive, figure 3.24A). After day 4, only the basal level 
of quiescent HSCs was observed distributed all over the liver lobule (α-SMA negative, 
desmin positive), (figure 3.35). Similarly, in clodronate treated mice, there was no 
evidence of reversion of activated HSCs to the quiescent state despite of the prolonged 
accumulation in the pericentral compartment of the liver lobule (figure 3.35).  
 
Figure 3. 35: Co-staining of desmin (red) and α-SMA (green) at different time intervals after treatment 
with APAP ± clodronate. The images show that activated HSCs are eliminated both in saline as well as 
clodronate treated mice without reversion to the quiescent state. However, removal of activated HSCs takes 
longer time in clodronate treated mice. Scale bars: 100 µm. 
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Another hypothesis was that activated HSCs undergo apoptosis in the absence of 
macrophages, perhaps triggered by other infiltrating immune cells. To validate this 
hypothesis, TUNEL staining was performed in saline as well as clodronate treated mice. 
TUNEL positive signal was not detectable in the saline treated mice at all tested time 
periods (figure 3.36). Interestingly, following macrophage removal by clodronate 
treatment massive apoptosis of HSCs was observed, particularly on days 4 and 8 after 
APAP intoxication. Apoptosis of HSCs was confirmed by co-localization of TUNEL and 
desmin staining (figure 3.36). In order to confirm these interesting findings, another 
mouse model was used in which acute liver injury was induced by administration of the 
hepatotoxic compound CCl4 (1.6 g/kg). Macrophages were depleted by i.v. administration 
of clodronate on day 3 after CCl4 injection and liver tissue sections were collected on days 
5 and 6 after CCl4 administration for analysis. Similar to the APAP model, removal of 
macrophages lead to prolonged presence of activated HSCs after recovery of the dead 
cell area (figure 3.37).  This was also not associated with reversion of activated HSCs to 
a quiescent state as evidenced by desmin and α-SMA co-staining (figure 3.38A). In 
accordance with the APAP model, a relatively a high number of apoptotic HSCs were 
detected on day 6 after CCl4 intoxication in the absence of macrophages (figure 3.38B). 
In conclusion, in absence of macrophages a less efficient apoptosis dependent 
mechanism is triggered to eliminate activated HSCs after acute liver injury. This 
stimulated me to investigate the trigger of the observed apoptotic mechanism. Can 
apoptosis of activated HSCs be induced by other infiltrating immune cells? In order to 
obtain an overview about the presence of infiltrating leukocytes, liver tissue sections from 
the clodronate treated mice were immunostained using antibodies against CD45; a pan 
leukocytes marker. Interestingly, massive leukocyte infiltration was observed between 
days 4 and 8 after APAP administration, the time when activated HSCs were eliminated 
(figure 3.39). These CD45 positive cells were arranged in clusters at the pericentral 
compartment of the liver lobule. Since these cells were negative for F4/80, they were not 
macrophages (figure 3.31B). In order to identify these infiltrating immune cells, tissue 
sections were immunostained using antibodies against B220 (a B cell marker), CD3 (a T 
cell marker) and LY6G (a marker of neutrophils). The results revealed that a significant 
fractions of these cell clusters were positive for B220 and CD3 indicating infiltration of B 
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and T cells, respectively (figures 3.40 and 3.41). LY6G staining showed no significant 
neutrophils infiltration both in clodronate as well as saline treated mice (figure 3.42). For 
further confirmation and identification of these infiltrating immune cells, a group of APAP 
treated mice were injected with clodronate or saline on day 2 and the liver was collected 
and homogenized on day 4 after APAP intoxication. Immune cells were isolated and 
prepared for flow cytometry analysis by staining with fluorescently labeled antibodies 
against CD45, CD3, CD4, CD8, NK cells, natural killer T (NKT) cells, B cells and dendritic 
cells. In accordance with the immunostaining results, clodronate treated mice showed 
higher CD45 positive cell numbers in comparison to the saline group (figure 3.43A). 
Further identification of these cells showed higher numbers of B, T, NK, NKT and dendritic 
cells in clodronate treated mice in comparison to the saline group (figure 3.43B). Finally, 
I investigated whether these findings are reproducible in another model of acute liver 
injury. Therefore, similar experiments were performed after administration of a single 
dose of CCl4 (1.6 g/kg). The mice were treated with clodronate or saline on day three after 
CCl4 administration and the livers were collected on days 5 and 6 for analysis. Similar to 
the results after APAP intoxication, clusters of CD45 positive, F4/80 negative immune 
cells were detected in the livers of clodronate treated mice (figure 3.44). Furthermore, 
significant fractions of these cells were B cells as evidenced by B220 immunostaining 
(figure 3.44). In conclusion, elimination of macrophages during liver regeneration 
following an acute challenge stimulates immune cells infiltration, particularly B, T, NK and 
dendritic cells, which might trigger the killing and elimination of activated HSCs. 
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Figure 3. 36: Activated HSCs are eliminated by apoptosis after macrophage depletion during liver 
regeneration. Liver tissue sections stained with TUNEL at different time periods after administration of 
APAP ± clodronate. (A) Saline treated mice showing TUNEL negative staining. (B) Clodronate treated mice 
showing massive apoptosis in the pericentral compartment of the liver lobule particularly on days 4 and 8 
after APAP intoxication. (C) Co-staining of TUNEL and desmin in clodronate treated mice confirming 
apoptosis of HSCs. Scale bars: 100 µm. (D) 3D reconstructions of desmin and TUNEL staining on day 4 
after APAP intoxication in clodronate treated mice showing a lot of apoptotic HSCs. 
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Figure 3. 37: Prolonged presence of activated HSCs after macrophage depletion. Mice were 
intoxicated with a single dose of CCl4 (1.6 g/kg) and received an i.v. injection of clodronate (50 mg/kg) or 
saline on day 3 after CCl4 administration. Immunostaining of F4/80 on days 5 and 6 after CCl4 intoxication 
shows the infiltration of macrophages into the pericentral compartment of the liver lobule in saline treated 
mice. In contrast, the liver appears almost free of macrophages after clodronate treatment. Immunostaining 
of desmin as well as α-SMA show prolonged presence of the activated HSCs in the absence of 
macrophages, although the dead cell area is recovered both in the saline as well as in the clodronate 
treated mice (H&E). Scale bars: 100 µm. 
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Figure 3. 38: Activated HSCs are slowly eliminated by apoptosis in the absence of macrophages 
after acute liver injury. Mice are intoxicated with a single dose of CCl4 (1.6 g/kg) and received an i.v. 
injection of clodronate (50 mg/kg) or saline on day 3 after CCl4 administration. (A) Desmin and α-SMA co-
staining showing that there is no reversion of HSCs from the active to the quiescent state neither in absence 
nor in presence of macrophages. (B) TUNEL and desmin co-staining showing a lot of apoptotic HSCs on 
day 6 after CCl4 intoxication in the absence of macrophages (clodrontae treated mice). Scale bars: 100 µm. 
 
 
 
 
 
 
 
 
Figure 3. 39: Massive leukocyte infiltration into the 
pericentral compartment of the liver lobule in absence of 
macrophages during regeneration from an acute liver 
injury. APAP pre-treated mice were injected with clodronate (50 
mg/kg) on day 2 after APAP injection and repeated every 3 days. 
CD45 immunostaining showing massive leukocytes infiltration 
arranged in clusters in the pericentral compartment particularly 
between days 4 and 8 after APAP administration. The lower 
panel shows higher magnification images of days 4 and 8. Scale 
bars: 100 µm. 
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Figure 3. 41: T cell infiltration during liver regeneration 
after removal of macrophages. Immunostaining of liver 
tissue sections using antibody against CD3 at different time 
intervals after administration of APAP (300 mg/kg) ± 
clodronate (50 mg/kg).The images show T cell infiltration 
between days 4 and 8 after APAP administration in clodronate 
treated mice. The lower panel shows higher magnification 
images of days 4 and 8. Scale bars: 100 µm. 
 
Figure 3. 40: B cell infiltration during liver regeneration 
after removal of macrophages. Immunostaining of liver 
tissue sections using antibody against B220 at different time 
intervals after administration of APAP (300 mg/kg) ± 
clodronate (50 mg/kg).The images show B cell infiltration 
between days 4 and 8 after APAP administration in clodronate 
treated mice. The lower panel shows higher magnification 
images of days 4 and 8. Scale bars: 100 µm. 
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Figure 3. 42: Neutrophils do not contribute to elimination of activated HSCs during liver 
regeneration. Liver tissue sections from mice treated with APAP ± clodronate were immunostained using 
antibodies against LY6G. The images show very few infiltrating neutrophils both in saline as well as 
clodronate treated mice. Scale bars: 100 µm. 
 
 
 
 
 
Figure 3. 43: Flow cytometry analysis of infiltrating leukocytes in liver tissues of APAP ± clodronate 
treated mice on day four after APAP injection. (A) CD45 positive cells showing more leukocytes in the 
livers of clodronate treated in comparison to saline treated mice. These cells are a mixture of B, T, NK, NKT 
and dendritic cells (B). Data are means ± SD of six mice. ***p<0.001, *p<0.05 when compared to the 
corresponding control (saline) group. 
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Figure 3. 44: Leukocytes infiltration during liver regeneration after CCl4 intoxication and depletion 
of macrophages. The images show leukocytes infiltration (CD45 positive) particularly B cell (B220 positive) 
in clodronate treated mice. F4/80 staining shows massive macrophages infiltration into the pericentral 
compartment of the liver lobule of the saline treated group. Scale bars: 100 µm.     
 
 
 
 
 
 
 
 
 
 
 
4.  Discussion 
  
103 
 
4. Discussion 
 
Unexpected findings of this thesis are: (1) massive activation of HSCs and infiltration into 
the dead cell area following acute liver injury, (2) activation of HSCs under these 
conditions is not associated with fibrosis development but, (3) the activated HSCs are 
efficiently eliminated by macrophages following recovery of the dead cell area, (4) 
removal of macrophages activate backup mechanisms for elimination of activated HSCs. 
 
4.1 Similar responses but different consequences of HSCs following acute and 
chronic liver damage scenarios 
 
It is well known that chronic liver injury leads to activation and trans-differentiation of 
quiescent HSCs into myofibroblast-like cells (Duffield et al. 2005; Henderson and Iredale 
2007; Tacke and Zimmermann 2014). Activation of HSCs results mainly of interaction 
with CD11bhi LY6Chi pro-inflammatory macrophages which infiltrate the liver tissue during 
the destruction process following liver intoxication (Baeck et al. 2014; Ju and Tacke 2016; 
Ramachandran et al. 2012; Zigmond et al. 2014). These pro-inflammatory macrophages 
produce: (1) TGF-β which activate the resting HSCs into myofibroblast-like cells 
(Ramachandran and Iredale 2012b; Seki et al. 2007); (2) platelet derived growth factor 
(PDGF), which stimulate proliferation and migration of HSCs into the site of injury (Tacke 
and Zimmermann 2014; Wang et al. 2016); and (3) IL-1β and TNF-α which stimulate the 
NF-kB pathway that maintains survival of activated HSCs (Pradere et al. 2013; Seki and 
Schwabe 2015) (figure 4.1). Activation of HSCs in case of chronic liver injury leads to 
production and accumulation of extracellular matrix (ECM) and fibrosis development 
(Baeck et al. 2014; Ramachandran and Iredale 2012a; Ramachandran and Iredale 
2012b) (figures 4.1 and 4.2).   
In contrast to chronic liver injury, despite of massive cell killing and activation of HSCs 
following administration of a single toxic dose of APAP or CCl4, liver fibrosis was not 
induced. Instead, perfect liver regeneration was obtained within a week following 
intoxication (figure 4.1). This suggests that liver fibrosis can develop only after repeated 
exposure to a hepatotoxic agent until a certain threshold is exceeded. The transient 
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massive activation of HSCs following acute liver damage may be critical for liver 
regeneration because: (1) HSCs can engulf apoptotic bodies of damaged hepatocytes 
which attenuates inflammation and triggers regeneration signals (Weiskirchen and Tacke 
2014). The engulfment of apoptotic bodies by HSCs also helps in its activation and 
stimulates survival pathways (Canbay et al. 2003; Jiang et al. 2009; Zhan et al. 2006). (2) 
Activated HSCs are known to produce hepatocyte growth factor (Skrtic et al. 1999; Yin et 
al. 2013), which is a potent hepatocyte mitogen. The present data show that 
administration of very high doses of APAP (450 mg/kg) lead to weak and delayed 
activation of HSCs. This was associated with delayed hepatocyte proliferation and 
compromised liver regeneration. Furthermore, (Shen et al. 2011) have reported that 
depletion of activated HSCs correlate with severe liver injury and compromised liver 
regeneration after APAP intoxication. (3) Infiltration of activated HSCs into the dead cell 
area may serve as a niche that stabilizes the wound until replacement proliferation takes 
place. 
 
 
Figure 4. 1: Different consequence to stellate cell activation in case of acute and chronic damage 
scenarios: following liver injury CD11bhi LY6Chi pro-inflammatory macrophages infiltrate the liver tissue 
and interact with HSCs via: (1) secretion of TGF-β which induce activation of HSCs; (2) platelet derived 
growth factor (PDGF), which stimulates proliferation of HSCs; and (3) IL-1β and TNF-α which promote 
survival of HSCs. After single intoxication the activation of HSCs occurs only transiently and disappears 
within few days without fibrosis development. In contrast, repeated liver injury leads to prolonged activation 
of HSCs and excessive deposition of extracellular matrix leading to liver fibrosis which may progress to 
cirrhosis. 
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4.2 Different mechanisms are responsible for removal of activated HSCs after acute 
and chronic damage scenarios 
 
In order to explain the discrepancy between fibrosis induction as a consequence of 
repeated intoxication and perfect regeneration following single intoxication, the 
mechanisms of activated HSCs elimination were studied in both scenarios. The present 
study demonstrates that despite of elimination of activated HSCs following both single 
(acute) and repeated (chronic) challenges, the responsible mechanisms are different 
(figure 4.3). Elimination of activated HSCs represents an active process. The responsible 
mechanisms have been extensively studied during fibrosis regression and include: (1) 
reversion of activated HSCs to an inactive phenotype (Friedman 2012; Kisseleva et al. 
2012; Troeger et al. 2012). However, these cells remain primed and are highly sensitive 
for rapid fibrogenesis if the injury is repeated (Kisseleva et al. 2012; Mallat and Lotersztajn 
2013). (2) Elimination of activated HSCs by apoptosis; the main players are NK cells, 
which induce killing of HSCs either directly in a TRAIL dependent manner or indirectly via 
production of IFN-γ (Radaeva et al. 2006; Tian et al. 2013); and the restorative (CD11bhi 
LY6Clo macrophages), which kill activated HSCs in a TRAIL dependent manner 
(Ramachandran and Iredale 2012b; Seki and Schwabe 2015; Tacke and Trautwein 
2015). In addition, these restorative macrophages are also a rich source of matrix 
metalloproteinases (MMPs) particularly MMP9, MMP12 and MMP13 which are important 
for degradation of ECM (Fallowfield et al. 2007; Ramachandran et al. 2012; Seki and 
Schwabe 2015; Tacke and Zimmermann 2014). (3) A fraction of activated HSCs also 
undergoes senescence during fibrosis recovery. This results in a phenotype with reduced 
fibrogenic properties that also more labile to immune cell induced killing (Kim et al. 2013; 
Krizhanovsky et al. 2008). All these mechanisms could be reproduced under our 
experimental setup following repeated CCl4 intoxication (figures 4.2 and 4.3). In contrast, 
none of these mechanisms were observed during regeneration after acute challenge. 
However, activated HSCs were rapidly removed. While the peak of HSCs activation can 
be seen between days 2 and 3 following APAP administration, it takes only until day 6 for 
all of them to be removed. The elimination of activated HSCs occurred during the time 
period when macrophages massively infiltrate the pericentral compartment of the liver 
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lobule. The present findings suggest direct engulfment of living activated HSCs by 
macrophages. This was supported by prolonged presence of activated HSCs upon 
macrophages depletion. Direct phagocytosis of living cells by macrophages was 
previously reported only for cancer cells. (Feng et al. 2015) reported that blocking of CD47 
(Do not eat me signal) on tumor cells allows their recognition and direct phagocytosis by 
macrophages.  
In conclusion, these data show that the extent of cell killing and activation of HSCs do not 
necessarily correlate with fibrosis induction. A balance between fibrotic and anti-fibrotic  
 
Figure 4. 2: Activation of HSCs during fibrosis progression and their elimination during fibrosis 
recovery. Following liver injury LY6Chi pro-inflammatory macrophages infiltrate the liver tissue and 
stimulate activation and proliferation of HSCs. After cessation of liver injury, activated HSCs disappear by 
reversion to inactive phenotype, apoptosis or senescence then apoptosis. The major cell types which are 
relevant for elimination of activated HSCs are LY6Clo macrophages, NK cells, dendritic cells and γδ-T cells 
(Source: Pellicoro et al. 2014). 
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Figure 4. 3: Different mechanisms for elimination of activated hepatic stellate cells (HSCs) after 
repeated (chronic) and single (acute) liver injury. After single or repeated liver injury HSCs get activated 
and become myofibroblast-like cells that produce excessive amount of extracellular matrix. However, after 
cessation of liver injury, activated HSCs are eliminated by different mechanisms. During fibrosis recovery, 
a fraction of activated HSCs reverts back to the quiescent state; another fraction undergoes apoptosis (the 
main players are NK cells, γδ-T cells, restorative macrophages and dendritic cells) and a third fraction first 
undergoes senescence and then becomes apoptotic. In contrast, during regeneration from a cute 
challenge, activated HSCs are eliminated via direct engulfment by macrophages. 
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4.3 Identification of backup mechanisms of activated HSCs elimination  
 
The present data revealed that activated HSCs are eliminated actively via direct 
engulfment by macrophages during liver regeneration after acute challenge. This is a very 
efficient process, since it does not allow ECM deposition. Elimination of macrophages by 
clodronate administration leads to prolonged presence of activated HSCs after single 
injection of a toxic dose of APAP or CCl4. This was associated with mild ECM 
accumulation in the pericentral compartment of the liver lobule. However, this effect was 
transient since activated HSCs as well as ECM were eliminated within 1-2 weeks. While 
looking for the responsible mechanism, there was no detectable reversion of activated 
HSCs to the quiescent state. However, interestingly massive apoptosis of activated HSCs 
was detected (figure 4.4). Since, it is already known that apoptosis of activated HSCs 
results mainly of interaction with immune cells, leukocytes infiltration was checked in 
clodronate treated livers by immunostaining using anti-CD45 antibodies. Surprisingly, 
massive leukocyte infiltration arranged in clusters was detected, particularly in the 
pericentral compartment of the liver lobule. Further characterization via flow cytometry 
and immunohistochemical analyses revealed that these cell clusters consist of B, T, NK 
as well as dendritic cells (figure 4.4). This suggests that these cell types are responsible 
for elimination of activated HSCs as well as degradation of ECM in absence of 
macrophages.  
NK cells are innate lymphoid cells and well known to possess anti-fibrotic properties and 
their blocking leads to enhanced liver fibrosis (Fasbender et al. 2016; Gao and Radaeva 
2013). The cytotoxicity of NK cells is triggered by activation of its stimulatory receptors as 
well as some cytokines particularly IFN-γ (discussed in details in the introduction section, 
figure 1.10). NK cells inhibit liver fibrosis by killing of HSCs directly via expression of the 
death receptor ligand TRAIL (Gao and Radaeva 2013; Gao et al. 2009; Tian et al. 2013). 
Another anti-fibrotic mechanism of NK cells is the production of IFN-γ (Gao and Radaeva 
2013; Gao et al. 2009; Tian et al. 2013; Weiskirchen and Tacke 2014). IFN-γ plays a duel 
role against activated HSCs: (1) direct inhibition of HSCs activation (Tian et al. 2013), and 
(2) upregulation of NKG2D (NK cells stimulatory receptor) and TRAIL expression on NK 
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cells which result in amplification of NK cells cytotoxicity against activated HSCs 
(Radaeva et al. 2006) (figure 4.5)  
 
 
 
 
 
 
 
 
 
Figure 4. 4: Identification of a second backup mechanism of elimination of activated HSCs after 
macrophage removal during liver regeneration following acute challenge. The primary pathway for 
elimination of activated HSCs following a single exposure to a hepatotoxic compound is the direct 
engulfment by macrophages. This is a very efficient mechanism and does not lead to deposition of 
extracellular matrix. Removal of macrophages stimulates infiltration of a backup system for elimination of 
activated HSCs, which consists of B, T, NK and dendritic cells. These infiltrating cells lead to massive 
apoptosis of activated HSCs. However, this backup mechanism is less efficient and leads to transient 
deposition of collagen; but the liver also return to the normal state within 8-16 days. 
 
Dendritic cells (DCs) are immature and tolerogenic in steady state (Lukacs-Kornek and 
Schuppan 2013). It was already reported that DCs exhibit fibrolytic properties after 
withdrawal of the causative agent of liver injury (Rahman and Aloman 2013; Seki and 
Schwabe 2015). Depletion of DCs during fibrosis recovery results in delayed resolution 
and reduced clearance of activated HSCs (Jiao et al. 2012; Ramachandran and Iredale 
2012a). However, the anti-fibrotic mechanism of DCs is not fully understood. Some 
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studies showed that dendritic cell enhance ECM degradation via production of MMP9 
(Jiao et al. 2012; Pellicoro et al. 2014; Ramachandran and Iredale 2012a; Tacke and 
Trautwein 2015). Other studies reported that DCs indirectly contribute to activated HSCs 
apoptosis via production of IFN-γ which induce NK cells activation (Okazaki et al. 2012; 
Tian et al. 2013) (figure 4.5). 
The role of T cells in fibrogenesis/fibrosis regression is still unclear and most likely 
depends on the causative agent (Pellicoro et al. 2014). Using mice which are deficient in 
CD4+ and CD8+ T cells showed no difference in fibrosis development or regression 
following toxic liver injury (Novobrantseva et al. 2005; Pellicoro et al. 2014). In contrast, 
other studies showed that fusion of T cells with HSCs leads to fibrosis regression by 
upregulation of anti-fibrotic genes (Kornek et al. 2011). There are two important subtypes 
of T cells which have been reported to interact with activated HSCs: CD4+ (T-helper) and 
gamma delta T (γδ-T) cells. CD4+TH cells are sub-classified into TH1, TH2 and TH17 cells 
(Heymann and Tacke 2016). The balance between TH1 and TH2 is important in response 
of CD4+ cells to fibrosis. When TH1 cells predominate this results in anti-fibrotic effects 
via the release of IFN-γ and IL-12. The later decreases expression of pro-fibrotic genes 
production by TH2 cells (Muhanna et al. 2008; Pellicoro et al. 2014). Additionally, CD4+ T 
cells induce activation of NK cells in a IL-2/NKG2D dependent manner, leading to 
amplification of NK cell cytotoxicity against activated HSCs (Fehniger et al. 2003; 
Glassner et al. 2013; He et al. 2004; Horowitz et al. 2010). The presence of DCs can also 
help in T cells activation via the production of IL-10 and TNF (Heymann and Tacke 2016; 
Mathan et al. 2013; Robinson et al. 2016). γδ-T cells represent 25% of liver T cell 
(Hammerich and Tacke 2014). Upon liver injury, γδ-T cells are recruited to the liver in a 
CCR6 – CCL20 chemokine dependent manner. These cells induce apoptosis of activated 
HSCs via expression of Fas ligand which binds to the death receptors Fas in activated 
HSCs (Hammerich et al. 2014). 
The role of B cells in fibrogenesis and fibrosis regression is still not fully understood. 
(Novobrantseva et al. 2005) reported that absence of B cells attenuates liver fibrosis. 
However, they did not show any mechanism by which B cells induce fibrosis. Several 
studies have shown that B cells are involved in T cell activation (Holt et al. 2008; Parekh 
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et al. 2003; Tian et al. 2001) and thereby may indirectly contribute to HSCs apoptosis.  
In conclusion, absence of macrophages during liver regeneration is replaced by a backup 
mechanism which induces apoptosis of activated HSCs and prevents liver fibrosis. This 
consists of NK cells, T cells (which induce apoptosis of activated HSCs), B cells (which 
activate T cells) and dendritic cells (which activate NK and T cells as well as induce matrix 
degradation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 5: Identification of backup mechanism for elimination of activated HSCs: in absence of 
macrophages massive infiltration of four cell types occurs during liver regeneration. The cooperation 
between these cells allows apoptosis of activated HSCs as well as degradation of extracellular matrix 
(ECM). These cells are: (1) NK cells, which induce apoptosis of activated HSCs; (2) T cells, which contribute 
to HSCs apoptosis and also amplify the cytotoxicity of NK cells via release of IL-2 and IFN-γ; (3) dendritic 
cells, which enhance ECM degradation via the release of MMP9 and also activate NK, B and T cells; and 
(4) B cells, which indirectly contribute to the elimination of activated HSCs via T cell activation. 
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5. Summary 
 
Liver fibrosis is a wound healing process in case of repeated liver injury characterized by 
activation of hepatic stellate cells (HSCs) and excessive accumulation of extracellular 
matrix (ECM). Depending on the duration and the nature of injury, liver fibrosis can be 
reversible; via elimination of activated HSCs and degradation of ECM. In contrast to 
chronic liver injury efficient liver regeneration occurs following acute liver injury without 
fibrosis development. However, little is known about the state of HSCs following acute 
liver injury. Here, our goal was to investigate HSCs dynamics during liver injury and 
regeneration and to identify the mechanisms that protect against liver fibrosis. For this 
purpose, mouse models of acute (single dose of acetaminophen or carbon tetrachloride, 
CCl4) and chronic (repeated CCl4 intoxication) liver injury were used. Induction of acute 
liver injury by APAP or CCl4 lead to massive killing of the pericentral hepatocytes. This 
was associated with massive activation and infiltration of HSCs into the dead cell area. 
However, these activated HSCs were efficiently eliminated within a week following liver 
injury without fibrosis development. In contrast, moderate cell killing and activation of 
HSCs following repeated liver injury lead to massive accumulation of ECM and fibrosis. 
Next, we investigated the mechanisms of activated HSCs elimination during liver recovery 
following acute and chronic damage scenarios. As already known, a fraction of activated 
HSCs reverts back to a quiescent phenotype during fibrosis recovery and a further 
fraction undergoes apoptosis. This effect was associated with massive infiltration of 
macrophages and NK cells. In contrast, although massive infiltration of macrophages was 
also observed following acute liver damage at the time when activated HSCs were 
eliminated, there was no reversion or apoptosis. It seems that activated HSCs are 
eliminated via direct engulfment by macrophages. This was supported by prolonged 
presence of activated HSCs after macrophage depletion. However, this prolonged 
preserve was transient, since activated HSCs were also eliminated within two weeks after 
induction of acute liver injury. Further analysis identified a backup mechanism of 
infiltrating immune cells (mainly B, T, NK and dendritic cells) which trigger apoptosis of 
activated HSCs in absence of macrophages. In conclusion, the efficient macrophage 
response following acute liver injury prevents liver fibrosis. When macrophages are 
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eliminated a backup mechanism of infiltrating immune cells becomes active and triggers 
apoptosis of activated HSCs. 
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6. Zusammenfassung 
 
Die Leberfibrose ist Folge eines Wundheilungsprozesses bei wiederholten 
Leberbeschädigungen. Sie ist durch die Aktivierung von Sternzellen der Leber (HSC) 
und die übermäßige Ablagerung von extrazellulärer Matrix charakterisiert. In 
Abhängigkeit von Art und Intensität kann Leberfibrose reversibel sein. Im Gegensatz 
zu chronischer Leberschädigung regeneriert ein akuter Leberschaden ohne Fibrose. 
Allerdings ist nur wenig über die Bedeutung von HSC bei akuter Leberschädigung 
bekannt. Das Ziel dieser Arbeit bestand darin, den zeitlichen Verlauf der Aktivierung 
und Entfernung von HSC nach akuter Leberschädigung zu untersuchen und zu 
verstehen, warum in diesem Fall im Gegensatz zur chronischen Situation keine 
Fibrose entsteht. Um dieses Ziel zu erreichen wurden Mausmodelle mit akuter 
(einzelne hepatotoxische Dosen von Paracetamol oder CCl4) und chronischer 
(wiederholte Applikation von CCl4) eingesetzt. Die Verursachung akuter 
Leberschädigung durch Paracetamol oder CCl4 führte wie erwartet zu einer massiven 
zentrilobulären Nekrose von Hepatozyten. Dies ging mit einer massiven Aktivierung 
von HSC und deren Einwanderung in das nekrotische Areal einher. Allerdings waren 
diese aktivierten HSC bereits eine Woche nach Induktion der Leberschädigung nicht 
mehr nachweisbar. Im Gegensatz zur akuten Situation führte die wiederholte 
Leberschädigung zu einer starken Anhäufung extrazellulärer Matrix (ECM) und 
Fibrose. Daher wurde als nächstes untersucht, welche Mechanismen zur Eliminierung 
der HSC im akuten und chronologischen Schadensszenario führen. Wie bereits 
bekannt wurde bei chronischer Schädigung beobachtet, dass aktivierte HSC entweder 
in einen ruhenden Zustand oder in Apoptose übergehen. Dies war mit einer starken 
Infiltration von natürlichen Killerzellen (NKC) und Makrophagen vergesellschaftet. Im 
Gegensatz zur chronischen Schädigung wurde nach akuter Intoxikation ebenfalls eine 
starke Infiltration von Makrophagen aber keine Apoptose von HSC beobachtet. 
Weitere Untersuchungen ergaben starke Hinweise darauf, dass aktivierte HSC in 
dieser Situation durch direkte Phagozytose durch Makrophagen entfernt werden. Dies 
konnte durch Depletion der Makrophagen bestätigt werden, wodurch es zu einer 
verlängerten Präsenz der HSC kam. Trotz der verlängerten Präsenz kam es jedoch zu 
einer späteren Entfernung der HSC innerhalb von etwa zwei Wochen nach akuter 
Leberschädigung. Weitere Untersuchungen zeigten, dass in diesem Zusammenhang 
andere Immunzellen als 
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Makrophagen, nämlich B-, T-, NK- und dendritische Zellen eine Rolle spielen. In 
Abwesenheit von Makrophagen scheinen diese die apoptische Antwort der HSC zu 
verursachen. Zusammenfassend kann festgestellt werden, dass es bei akuter 
Leberschädigung zu einer sehr effizienten Entfernung von aktivierten HSC durch 
Makrophagen kommt, wodurch Leberfibrose verhindert wird. Falls diese 
Makrophagenantwort eliminiert wird, kommt es zu einem Ersatzmechanismus 
infiltrierender Immunzellen, wodurch Apoptose von HSC verursacht wird.           
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